Acidic skin and / or hair compositions and methods thereof
The combination of purified glycolic acid with plant extracts in topical compositions addresses the stability and efficacy challenges of existing formulations, offering a stable and effective solution for skin and hair care without formaldehyde, enhancing cosmetic outcomes and shelf life.
Patent Information
- Application Number
- PCT/US2024/029876
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Existing topical skin and hair compositions that combine alpha hydroxy acids (AHAs) and beta hydroxy acids (BHAs) with other active ingredients face challenges in maintaining stability and efficacy, often containing toxic compounds like formaldehyde, and struggle to incorporate multiple actives effectively in a single formulation.
A composition comprising purified glycolic acid, either in solubilized or crystalline form, combined with plant extracts like maqui berry extract, anthocyanin, and delphinidin, which allows for a synergistic effect, increased stability, and cost-effective production, while avoiding formaldehyde and enabling the addition of multiple actives in one step.
The solution provides a stable, effective, and cost-efficient topical composition that enhances skin and hair health by maintaining the stability of active ingredients, reducing oxidation, and improving cosmetic efficacy without formaldehyde, with improved shelf life and thermal stability.
Smart Images

Figure IMGF000051_0001 
Figure IMGF000030_0001 
Figure IMGF000030_0002
Abstract
Description
ACIDIC SKIN AND / OR HAIR COMPOSITIONS AND METHODS THEREOFBACKGROUND OF THE INVENTION
[0001] This application claims priority of U.S. Provisional Patent Application No. 63 / 467,441, filed May 18, 2023, which is hereby incorporated by reference in its entirety.A. Field of the Invention
[0002] The present invention relates generally to the fields of topical skin and / or hair compositions. More particularly, it concerns an acidic composition including a combination of a skin and / or hair active ingredient, and an alpha hydroxy acid (AHA) and / or a beta hydroxy acid (BHA). The topical skin and / or hair composition can be acidic to provide a composition with increased stability and / or efficacy, such as cosmetic efficacy.B. Description of Related Art
[0003] The epidermis, the outermost layer of the skin, acts as a barrier against environmental damage and regulates the release of water into the atmosphere. Damage to this layer can impede moisturization and the shedding of dead skin cells, affecting the skin's overall appearance. Ultraviolet (UV) radiation can cause damage to the epidermis, leading to sunburn, wrinkles, and an increased risk of skin cancer. Damage to the epidermis, whether caused by UV radiation, injury, or other factors, can lead to various skin conditions such as irritation, hyperpigmentation, and / or erythema. Similarly, the F-layer, also known as the cuticle layer, is the outermost layer of a hair fiber. It is composed of lipids, which form a protective barrier around the hair shaft. These lipids help to retain moisture and protect the hair from damage caused by environmental factors such as heat, chemicals and ultraviolet radiation. Damage to the F-layer can lead to dry, brittle, and damaged hair. Proper care and maintenance of the F- layer, including protecting the hair from UV rays, can help provide for healthy, strong, and / or shiny hair.
[0004] Stresses on the skin and hair can be caused by various factors and can change the appearance, physical properties, and physiological functions of the skin and hair in ways that are not desirable. Chemical exfoliants like AHAs and BHAs can help repair and prevent damage to the skin and hair by removing dead skin cells, unclogging pores, stimulating collagen production and helping to smooth out the hair cuticle. Many consumers desire nontoxic skin and / or hair compositions that comprise chemical exfoliants such as AHAs and / orBHAs. However, many compositions that comprise chemical exfoliants contain toxic compounds. For example, US 8299297 B2 discloses production of glycolic acid by carbonylation of formaldehyde. Another common method of producing glycolic acid is disclosed in US 763861782 B2 which discloses the enzymatic production of glycolic acid from glycolonitrile. Both of these methods of producing glycolic acid yield a glycolic acid product that comprises residual traces of formaldehyde. Formaldehyde is recognized by the Environmental Protection Agency as a probable carcinogen. Therefore, conscious consumers desire chemical exfoliant compositions that do not comprise formaldehyde. Many other attempts at cosmetic skin and / or hair compositions have been unsuccessful at providing a formaldehyde-free glycolic acid.
[0005] Consumers would like to obtain the benefits of multiple actives in one product. Further many consumers desire topical skin and / or hair compositions that comprise a chemical exfoliant along with another skin and / or hair active ingredient. The combination of a skin and / or hair active ingredient with a chemical exfoliant is desirable as chemical exfoliants allow for better absorption or added benefits with topical application of another skin and / or hair active ingredient. Many attempts have been made at combining AHAs and / or BHAs with other skin and / or hair active ingredients. However, these attempts have been unsuccessful at allowing both the chemical exfoliant[s] and the other skin and / or hair active ingredients] to remain effective when combined together.
[0006] Further, formulators desire cosmetic compositions that make the process of creating a cosmetic formulation more manageable to help ensure that ingredients are added at the correct time and in the correct order for optimal stability, texture, and / or performance of the final product. Many attempts have been unsuccessful at allowing formulators to add chemical exfoliants with other skin and / or hair active ingredients in one step or sub-phase.SUMMARY OF THE INVENTION
[0007] In one aspect of the present invention, a solution to at least one or more of the aforementioned deficiencies in the art is provided. By way of example, the present invention discloses a skin and or hair composition that comprises a skin and / or hair active ingredient and an AHA and / or BHA. In one particular aspect, the glycolic acid can be a purified glycolic acid and / or the skin or hair active can include anthocyanin, delphinidin, and / or ellagic acid. The purified glycolic acid that can be added to a composition of the present invention can be (1) a solubilized glycolic acid in a solution such that at least 60 wt. %, preferably at least 70 wt. %,or more preferably 65 wt. % to 75 wt. %, or at least 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 85, 90, 95, 96, 97, 98, or 99 wt. % or more of the solution contains solubilized glycolic acid, and / or (2) a crystalline form of glycolic acid that is at least 90 wt. %, preferably 95 wt. %, or more preferably at least 99 wt. % of glycolic acid. The purified glycolic acid can be formaldehyde free. An advantage of using the purified glycolic acid in combination with skin and / or hair actives ingredients (e.g., anthocyanin, delphinidin, and / or ellagic acid) allows for the addition of multiple actives in a composition in one step or sub-phase, which can lead to simplicity in formulating, cost-effective production, increased cosmetic efficacy, and / or a synergistic effect.
[0008] In another aspect, the skin and / or hair active ingredient comprises a plant extract, a hydrophobic compound, and / or a hydrophilic compound. In one embodiment, the skin and / or hair active ingredient is a plant extract. The plant extract can be an aqueous extract, an alcohol extract, a supercritical CO2 extract, an oil extract, a maceration extract, etc., or a combination thereof. In some embodiments, the plant extract is an extract from a plant in the Araucariaceae, Cupressaceae, Pinaceae, Podocarpaceae, Sciadopitaceae, Taxaceae, Cycadaceae, Ginkgoaceae, Aceraceae, Agavaceae, Anacardiaceae, Annonaceae, Apocynaceae, Aquifoliaceae, Araliaceae, Arecaceae, Asphodelaceae, Asteraceae, Berberidaceae, Betulaceae, Bignoniaceae, Bombacaceae, Boraginaceae, Burseraceae, Buxaceae, Canellaceae, Cannabaceae, Capparidaceae, Caprifoliaceae, Caricaceae, Casuarinaceae, Celastraceae, Cercidiphyllaceae, Chrysobalanaceae, Clusiaceae, Combretaceae, Cornaceae, Cyrillaceae, Davidsoniaceae, Ebenaceae, Elaeagnaceae, Ericaceae, Euphorbiaceae, Fabaceae, Fagaceae, Grossulariaceae, Hamamelidaceae, Hippocastanaceae, Illiciaceae, Juglandaceae, Lauraceae, Lecythidaceae, Lythraceae, Magnoliaceae, Malpighiaceae, Malvaceae, Melastomataceae, Meliaceae, Moraceae, Moringaceae, Muntingiaceae, Myoporaceae, Myricaceae, Myrsinaceae, Myrtaceae, Nothofagaceae, Nyctaginaceae, Nyssaceae, Olacaceae, Oleaceae, Oxalidaceae, Pandanaceae, Papaveraceae, Phyllanthaceae, Pittosporaceae, Platanaceae, Poaceae, Polygonaceae, Proteaceae, Punicaceae, Rhamnaceae, Rhizophoraceae, Rosaceae, Rubiaceae, Rutaceae, Salicaceae, Sapindaceae, Sapotaceae, Simaroubaceae, Solanaceae, Staphyleaceae, Sterculiaceae, Strelitziaceae, Styracaceae, Surianaceae, Symplocaceae, Tamaricaceae, Theaceae, Theophrastaceae, Thymelaeaceae, Tiliaceae, Ulmaceae, Verbenaceae, and / or Vitaceae family. In some embodiments, the plant extract is a maqui berry extract, also known as Aristotelia chilensis extract. In some embodiments, the skin and / or hair active ingredient comprises one or more antioxidants, anti-inflammatories, moisturizers, pharmaceutical drugs, cosmetic activeingredients, fragrances, dyes and coloring ingredients, aroma agents, adsorbents, solvents, film formers, water-repellants, UV absorbers, essential oils, vitamins, trace metals, anti-irritants, anti-microbial agents, chelating agents, preservatives, pH adjusters, skin bleaching and lightening agents, humectants, exfoliants, waterproofing agents, skin conditioning agents, and / or skin darkening agents.
[0009] Further, in another aspect the composition comprises an effective amount of maqui berry extract to reduce oxidation of the skin and / or hair, decrease expression of tyrosinase, chelate copper, decrease skin redness, decrease melanin production, protect lipids of the F-layer of a hair fiber, maintain hydrophobicity of the skin and / or hair, maintain low porosity of hair, hydrate skin and / or hair, strengthen bonds of hair, and / or provide static charge to skin and / or hair when applied to skin and / or hair. Further, in one embodiment the maqui berry extract is an aqueous, alcoholic, or hydro-alcoholic extract. In another aspect the skin and / or hair active ingredient comprises an anthocyanin, delphinidin, and / or ellagic acid. In some instances, the composition may comprise the skin and / or hair active ingredient and an AHA and / or or a BHA. In some instances, the skin and / or hair active ingredients are comprised in the composition at a concentration of 1%, 2, 5%, 10%, and 15%.
[0010] In one aspect, the composition comprises an AHA comprising glycolic acid. In another aspect, the AHA is any one of, any combination of, or all of glycolic acid, lactic acid, mandelic acid, maleic acid, citric acid, and / or tartaric acid. In another embodiment, the composition comprises a BHA comprising any one of, any combination of, or all of salicylic acid and / or betaine salicylate. Further, in another embodiment, the composition does not comprise formaldehyde.
[0011] In another aspect, the composition comprises any one of, any combination of, or all of water, glycerin, a skin and / or hair active ingredient, such as maqui berry extract, and a AHA and / or BHA. Further, in another embodiment, the composition provides a synergistic effect.
[0012] The acidic skin and / or hair composition, in a non-limiting aspect, is formulated as a toner or gel. In another aspect the acidic skin and / or hair composition is formulated as an emulsion, serum, gel, gel emulsion, gel serum, a cream, a cream-gel, a lotion, an oil, a cleanser, toner, or a solution.
[0013] Methods of use for any embodiment of the compositions disclosed herein are also disclosed. In one aspect, the compositions disclosed are acidic topical skin and / or haircompositions comprising topically applying to the skin and / or hair in need thereof a composition comprising a skin and / or hair active ingredient and an AHA and / or a BHA. In some instances, the method comprises topically applying any one of the compositions disclosed herein to skin and / or their in need thereof. In one aspect, any one of the compositions disclosed herein are topically applied and the composition is left on the application area, removed from the application area after a period of time, and / or removed directly after application.
[0014] In several embodiments, the acidic topical skin and / or hair composition described herein offers protection to skin and / or hair active ingredients (e.g., plant extracts, such as maqui berry extracts, non-plant extracts, and / or combinations of any of the foregoing) against degradation in an aqueous environment for long-term storage. In several embodiments, the composition is well characterized to ensure a consistent product from batch to batch and with long-term stability. In several embodiments, the product stability may be tested for appearance, particle size, particle distribution, zeta potential, structure, pH, residual solvents, heavy metals, skin and / or hair active ingredient concentration, and / or microorganisms. In some instances, the values obtained from measurements using these test methods varies over time , such as at least about 1 month, at least about 3 months, at least about 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more, at room temperature, by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. As a non-limiting example, the concentration of the skin and / or hair active ingredients varies over a period of at least about 1 month, at least about 3 months, at least about 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more, at room temperature, by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. As another non-limiting example, the skin and / or hair efficacy of the composition varies over a period of at least about 1 month, at least about 3 months, at least about 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more, at room temperature, by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. As another non-limiting example, the structure of the composition, such as particle size, particle distribution, and / or distribution of ingredients of the composition, varies over a period of at least about 1 month, at least about 3 months, at leastabout 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, or more, at room temperature, by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 10%, 20%, 30%, or ranges including and / or spanning the aforementioned values. Particle size, particle distribution, and distribution of the ingredients of a composition, such as distribution in a particle or oil phase or aqueous phase, or within a matrix, etc., can be measured using conventional techniques.
[0015] In several embodiments, the formulations and / or compositions disclosed herein are stable during sterilization. In several embodiments, the sterilization may include one or more of ozonation, UV treatment, heat treatment (e.g., pasteurization), filtration, and / or gamma irradiation. In several embodiments, the appearance, particle size, particle distribution, zeta potential, structure, pH, residual solvents, heavy metals, skin and / or hair active ingredient concentration, etc. after sterilization (e.g., exposure to techniques that allow sterilization of the composition) varies (e.g., drops) by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 10%, 15%, or ranges including and / or spanning the aforementioned values as compared to the formulations and / or compositions before sterilization.
[0016] In several embodiments, the acidic skin and / or hair compositions (including after stabilization) disclosed herein have a shelf life of equal to or greater than 6 months, 12 months, 14 months, 16 months, 18 months, 2 years, 3 years, 4 years, 5 years, or ranges including and / or spanning the aforementioned values. The shelf life can be determined as the period of time in which there is 95% confidence that at least 50% of the stability property tested (e.g., skin and / or hair active ingredient(s) concentration or particle size) is within the specification limit. This refers to a 95% confidence interval and when linear regression predicts that at least 50% of the stability property tested is within the set specification limit.
[0017] In several embodiments the acidic skin and / or hair compositions disclosed herein have improved shelf life due in part to the acidity of the composition. For example, in several embodiments, the compositions disclosed remain solubilized for a period greater than or equal to 6 months, 12 months, 14 months, 16 months, 18 months, 2 years, 3 years, 4 years, 5 years, or ranges including and / or spanning the aforementioned values. The shelf life can be determined as the period of time in which there is 95% confidence that at least 50% of the stability property tested (skin and / or hair active ingredient(s) concentration or particle size) is within the specification limit. This refers to a 95% confidence interval and when linearregression predicts that at least 50% of the stability property tested is within a specification limit.
[0018] In several embodiments, the shelf life is determined as a time where the concentration of the active ingredient has changed (e.g., lessened) by less than or equal to 15%, 10%, 5%, 2.5%, or ranges including and or spanning the aforementioned ranges.
[0019] In several embodiments, the compositions disclosed herein, when provided in an acidic composition, have improved thermal stability, such as stability during thermal sterilization. Thermal sterilization may include exposing and / or heating a composition to a temperature of equal to or at least about 100 °C. In several embodiments, thermal sterilization is performed for a time period of equal to or at least about: 10 minutes, 15 minutes, 30 minutes, 60 minutes, or ranges including and / or spanning the aforementioned values.
[0020] In several embodiments, the acidic hair and / or skin compositions disclosed herein, after a storage period of equal to or at least about 15 days, 30 days, 45 days, 60 days, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, or 5 years, the concentration of the skin and / or hair active ingredients (e.g., plant extracts, such as maqui berry extracts, non-plant extracts, and / or combinations of any of the foregoing) in the composition drops by less than or equal to about: 0.25%, 0.5%, 0.75%, 1%, 1.5%, 2.0%, 2.5%, 5%, 7.5%, 10%, 15%, or ranges including and / or spanning the aforementioned values. In several embodiments, the storage conditions include temperatures of equal to or at least about: 2°C, 8°C, 10°C, 20°C, 40°C, 60°C, or ranges including and / or spanning the aforementioned values.
[0021] In several embodiments, the compositions disclosed herein are stable during sterilization during preparation and packaging. In several embodiments, the skin and / or hair active ingredients (e.g., plant extracts, such as maqui berry extracts, non-plant extracts, and / or combinations of any of the foregoing) concentration after sterilization (e.g., exposure to techniques that allow sterilization of the composition) drops by less than or equal to about: 0.05%, 0.1%, 0.5%, 1%, 5%, 10%, 15%, or ranges including and / or spanning the aforementioned values. In several embodiments, after sterilization, the acidic skin and / or hair compositions have a shelf life of equal to or greater than 6 months, 12 months, 14 months, 16 months, 18 months, 2 years, 3 years, 4 years, or 5 years, or ranges including and / or spanning the aforementioned values (e.g., at standard storage conditions).
[0022] In particular aspects, the compositions of the present invention are formulated as a topical skin composition. The composition can have a dermatologically acceptable vehicle or carrier for the compounds, compositions, and extracts. The composition can further include a moisturizing agent or a humectant, a surfactant, a silicone containing compound, a UV agent, an oil, and / or other ingredients identified in this specification or those known in the art. The composition can be a lotion, cream, body butter, mask, scrub, wash, gel, serum, emulsion (e.g., oil-in-water, water-in-oil, silicone-in-water, water-in- silicone, water-in-oil-in-water, oil-in- water-in-oil, oil-in-water-in-silicone, etc.), solutions (e.g., aqueous or hydro-alcoholic solutions), anhydrous bases (e.g., lipstick or a powder), ointments, milk, paste, aerosol, solid forms, eye jellies, etc. The composition can be in powdered form (e.g., dried, lyophilized, particulate, etc.). The composition can be formulated for topical skin application at least 1, 2, 3, 4, 5, 6, 7, or more times a day during use. In some aspects of the present invention, compositions can be storage stable or color stable, or both. It is also contemplated that the viscosity of the composition can be selected to achieve a desired result, e.g., depending on the type of composition desired, the viscosity of such composition can be from about 1 cps to well over 1 million cps or any range or integer derivable therein (e.g., 2 cps, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000, 2000000, 3000000, 4000000, 5000000, 10000000, cps, etc., as measured on a Brookfield Viscometer using a TC spindle at 2.5 rpm at 25°C).
[0023] The compositions of the present invention can also be modified to have a desired oxygen radical absorbance capacity (ORAC) value. In certain non-limiting aspects, the compositions of the present invention or the component or extracts thereof identified throughout this specification can be modified to have an ORAC value per mg of at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 15000, 20000, 30000, 50000, 100000 or more or any range derivable therein.
[0024] The compositions, in non-limiting aspects, can have a pH of about 3 to about 5. In some aspects, the pH can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, such as between 3 to 5, 3.5 to 5, 4.8 to 7, 3 to 7, 3.8 to 4.5, 4.5 to 7, etc. The compositions can include a triglyceride. Non-limiting examples include small, medium, and large chain triglycerides. Incertain aspects, the triglyceride is a medium chain triglyceride (e.g., caprylic capric triglyceride). The compositions can also include preservatives. Non-limiting examples of preservatives include phenoxyethanol, methylparaben, propylparaben, or any mixture of thereof. In some embodiments, the composition is paraben-free.
[0025] Compositions of the present invention can have UVA and UVB absorption properties. The compositions can have an sun protection factor (SPF) of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more, or any integer or derivative therein. The compositions can be sunscreen lotions, sprays, or creams.
[0026] The compositions of the present invention can also include any one of, any combination of, or all of the following additional ingredients: water, a conditioning agent, a chelating agent, a moisturizing agent, a pH adjuster, inorganic salts, a preservative, a thickening agent, a silicone containing compound, an essential oil, a structuring agent, a vitamin, a pharmaceutical ingredient, or an antioxidant, or any combination of such ingredients or mixtures of such ingredients. In certain aspects, the composition can include at least two, three, four, five, six, seven, eight, nine, ten, or more, or all of these additional ingredients identified in the previous sentence. Non-limiting examples of these additional ingredients are identified throughout this specification and are incorporated into this section by reference. The amounts of such ingredients can range from 0.0001% to 99.9% by weight or volume of the composition, or any integer or range in between as disclosed in other sections of this specification, which are incorporated into this paragraph by reference.
[0027] Kits that include the compositions of the present invention are also contemplated. In certain embodiments, the composition is comprised in a container. The container can be a bottle, dispenser, or package. The container can dispense a pre-determined amount of the composition. In certain aspects, the compositions is dispensed in a spray, mist, dollop, or liquid. The container can include indicia on its surface. The indicia can be a word, an abbreviation, a picture, or a symbol.
[0028] It is also contemplated that the compositions disclosed throughout this specification can be used as a leave-on or rinse-off composition. By way of example, a leave- on composition can be one that is topically applied to skin and / or hair and remains on the skin and / or hair for a period of time (e.g., at least 5, 6, 7, 8, 9, 10, 20, or 30 minutes, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours, or overnight or throughout the day). Alternatively, a rinse-off composition can be a product that is intendedto be applied to the skin and / or hair and then removed or rinsed from the skin and / or hair (e.g., with water) within a period of time such as less than 5, 4, 3, 2, or 1 minute. An example of a rinse off composition can be a skin cleanser, skin mask, hair mask, shampoo, conditioner, or soap. An example of a leave-on composition can be a skin moisturizer, sunscreen, mask, overnight cream, serum, hair serum, scalp serum, leave-in conditioner, oil, or a day cream.
[0029] It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.
[0030] In some embodiments, compositions of the present invention can be pharmaceutically or cosmetically elegant or can have pleasant tactile properties. “Pharmaceutically elegant,” “cosmetically elegant,” and / or “pleasant tactile properties” describes a composition that has particular tactile properties which feel pleasant on the skin (e.g., compositions that are not too watery or greasy, compositions that have a silky texture, compositions that are non-tacky or sticky, etc.). Pharmaceutically or cosmetically elegant can also relate to the creaminess or lubricity properties of the composition or to the moisture retaining properties of the composition.
[0031] Also contemplated is a product comprising a composition of the present invention. In non-limiting aspects, the product can be a cosmetic product. The cosmetic product can be those described in other sections of this specification or those known to a person of skill in the art. Non-limiting examples of products include a moisturizer, a cream, a lotion, a skin softener, a serum, a gel, a wash, a body butter, a scrub, a foundation, a night cream, a lipstick, a cleanser, a toner, a sunscreen, a mask, an anti-aging product, a deodorant, an antiperspirant, a perfume, a cologne, etc.
[0032] Also disclosed are the following Aspects 1 to 20 of the present invention. Aspect 1 is a method of treating skin and / or hair in need thereof, the method comprising topically applying to the skin and / or hair an acidic composition comprising: a skin and / or hair active ingredient; and an alpha hydroxy acid and / or a beta hydroxy acid.
[0033] Aspect 2 is the method of Aspect 1, wherein the skin and / or hair active ingredient comprises a plant extract.
[0034] Aspect 3 is the method of any one of Aspects 1 to 2, wherein the skin and / or hair active ingredient comprises an anthocyanin, delphinidin, and / or ellagic acid.
[0035] Aspect 4 is the method of any one of Aspects 1 to 3, wherein the skin and / or hair active ingredient comprises maqui berry extract.
[0036] Aspect 5 is the method of any one of Aspects 1 to 4, wherein the alpha hydroxy acid is glycolic acid, lactic acid, mandelic acid, and / or tartaric acid and / or wherein the beta hydroxy acid is salicylic acid and / or betaine salicylate.
[0037] Aspect 6 is the method of any one of Aspects 1 to 5, wherein the composition is an emulsion, serum, gel, gel emulsion, gel serum, a cream, a cream-gel, a lotion, an oil, a cleanser, or a solution.
[0038] Aspect 7 is the method of any one of Aspects 1 to 6, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the maqui berry extract is an aqueous, alcoholic, or hydro-alcoholic extract.
[0039] Aspect 8 is the method of any one of Aspects 1 to 7, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the composition comprises an effective amount of maqui berry extract to reduce oxidation of the skin and / or hair, decrease expression of tyrosinase, chelate copper, decrease skin redness, decrease melanin production, protect lipids of the F-layer of a hair fiber, maintain hydrophobicity of the skin and / or hair, maintain low porosity of hair, hydrate skin and / or hair, strengthen bonds of hair, and / or provide static charge to skin and / or hair when applied to skin and / or hair.
[0040] Aspect 9 is the method of any one of Aspects 1 to 8, wherein the composition does not comprise formaldehyde.
[0041] Aspect 10 is the method of any one of Aspects 1 to 9, wherein the composition comprises an alpha hydroxy acid comprising glycolic acid.
[0042] Aspect 11 is an acidic topical skin composition comprising: a skin and / or hair active ingredient; and an alpha hydroxy acid and / or a beta hydroxy acid.
[0043] Aspect 12 is the composition of Aspect 11, wherein the skin and / or hair active ingredient comprises a plant extract.
[0044] Aspect 13 is the composition of any of Aspects 11 to 12, wherein the skin and / or hair active ingredient comprises an anthocyanin, delphinidin, and / or ellagic acid.
[0045] Aspect 14 is the composition of any of Aspects 11 to 13, wherein the skin and / or hair active ingredient comprises maqui berry extract.
[0046] Aspect 15 is the composition of any one of Aspects 11 to 14, wherein the alpha hydroxy acid is glycolic acid, lactic acid, mandelic acid, and / or tartaric acid and / or wherein the beta hydroxy acid is salicylic acid and / or betaine salicylate.
[0047] Aspect 16 is the composition of any of Aspects 11 to 15, wherein the composition is an emulsion, serum, gel, gel emulsion, gel serum, a cream, a cream-gel, a lotion, an oil, a cleanser, or a solution.
[0048] Aspect 17 is the composition of any of Aspects 11 to 16, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the maqui berry extract is an aqueous, alcoholic, or hydro-alcoholic extract.
[0049] Aspect 18 is the composition of any of Aspect 11 to 17, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the composition comprises an effective amount of maqui berry extract to reduce oxidation of the skin and / or hair, decrease expression of tyrosinase, chelate copper, decrease skin redness, decrease melanin production, protect lipids of the F-layer of a hair fiber, maintain hydrophobicity of the skin and / or hair, maintain low porosity of hair, hydrate skin and / or hair, strengthen bonds of hair, and / or provide static charge to skin and / or hair when applied to skin and / or hair.
[0050] Aspect 19 is the composition of any one of Aspects 11 to 18, wherein the composition does not comprise formaldehyde.
[0051] Aspect 20 is the composition of any one of Aspects 11 to 19, wherein the composition comprises an alpha hydroxy acid comprising glycolic acid.
[0052] “Topical application” means to apply or spread a composition onto the surface of lips or keratinous tissue. “Topical skin and / or hair composition” includes compositions suitable for topical application on skin, lips, scalp, hair, and / or keratinous tissue. Such compositions are typically dermatologically-acceptable in that they do not have undue toxicity, incompatibility, instability, allergic response, and the like, when applied to lips, skin, scalp, hair, and / or keratinous tissue. Topical skin and / or hair care compositions of the present invention can have a selected viscosity to avoid significant dripping or pooling after application to lips, skin, scalp, hair, and / or keratinous tissue.
[0053] The term “about” or “approximately” are defined as being close to as understood by one of ordinary skill in the art. In one non-limiting embodiment the terms aredefined to be within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%.
[0054] The term “substantially” and its variations are defined as being largely but not necessarily wholly what is specified as understood by one of ordinary skill in the art, and in one non-limiting embodiment substantially refers to ranges within 10%, within 5%, within 1%, or within 0.5%.
[0055] The terms “inhibiting” or “reducing” or any variation of these terms includes any measurable decrease or complete inhibition to achieve a desired result. The terms “promote” or “increase” or any variation of these terms includes any measurable increase, such as a measurable increase of a protein, molecule, shelf life, etc.
[0056] The term “effective,” as that term is used in the specification and / or claims, means adequate to accomplish a desired, expected, or intended result.
[0057] The use of the word “a” or “an” when used in conjunction with the terms “comprising,” “including,” “having,” or “containing,” or any variations of these terms, in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
[0058] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0059] The compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of’ any of the ingredients or steps disclosed throughout the specification. With respect to the phrase “consisting essentially of,” a basic and novel property of the compositions and methods of the present invention is the ability to treat skin and / or hair.
[0060] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the examples, while indicating specific embodiments of the invention, are given by way of illustration only. Additionally, it is contemplated that changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0061] As noted above, several of the unique aspects of the present invention are to provide a stable, effective, and / or improved composition that is capable of treating skin and / or hair. This allows for benefit such as reducing irritation, reducing the effects of aging, smoothing texture of skin, smoothing hair cuticle, and / or increased cosmetic efficacy.
[0062] Some compositions disclosed herein are designed to work as a topical skin and / or hair composition. The composition relies on a unique combination of any one of, any combination of, or all of a skin and / or hair active ingredient, and an AHA and / or BHA. Nonlimiting examples of such a composition are provided in Example 1, Table 1.
[0063] Some compositions disclosed herein can be applied to the skin or hair and remain on the skin or hair for a period of time (e.g., at least 1, 2, 3, 4, 5, 10, 20, 30, or 60 minutes or more). After which, the composition, if needed, can be rinsed from the skin or peeled from the skin. Some compositions disclosed herein can be applied to the skin and immediately rinsed from the skin. Some compositions disclosed herein can be applied to the skin and absorbed at least in part by the skin.
[0064] These and other non-limiting aspects of the present invention are described in the following sections.A. Active Ingredients
[0065] In one aspect, the present invention concerns, at least in part, a discovery that a combination of one or more of an alpha hydroxy acid, a beta hydroxy acid, and / or a skin and / or hair active ingredient, such as a maqui berry extract, can be used to treat skin and / or hair.
[0066] A non-limiting example of a skin and / or hair active ingredient includes a Maqui berry extract. Maqui berry extract is a natural extract derived from the fruit of the Chilean maqui tree (Aristotelia chilensis). It is rich in antioxidants, including ellagic acid and a variety of anthocyanins. Ellagic acid is a powerful antioxidant that helps to protect the skin from damage caused by free radicals. It also has anti-inflammatory properties and can help to reduce the appearance of fine lines and wrinkles. Anthocyanins are a group of flavonoids that give fruits and vegetables their red, blue, and purple color. These powerful antioxidants are known to protect the skin from damage caused by UV radiation, pollution, and other environmental factors. Delphinidins, a specific type of anthocyanin, have been shown to be particularly potent in their antioxidant activity. Additionally, it can help to nourish and strengthen the hair,improving its overall health. Maqui berry extract can be an extract obtained by extraction using a solvent such as water, glycerin, ethanol, oil, CO2, or a combination thereof. Maqui berry extract may be commercially available. Non-limiting examples of commercially available Maqui berry extract include LUMIGLOW™ supplied by NOVACHEM SRL, and CAPILACID™ supplied by NOVACHEM SRL.
[0067] Alpha hydroxy acids (AHAs) are a group of naturally occurring acids that may be derived from fruits and other natural sources. AHAs contain a carboxylic acid and a hydroxyl group on the alpha carbon. They are used in a variety of personal care products such as skin and hair care products. One of the most commonly used AHAs is glycolic acid. Glycolic acid is a small molecule that can penetrate the skin easily. It works by exfoliating the outermost layer of the skin, removing dead skin cells and revealing the smoother, brighter skin underneath. Some benefits of glycolic acid include: improving the appearance of fine lines and wrinkles, enhancing skin texture and tone, reducing the appearance of hyperpigmentation and age spots, improving the overall health and appearance of the skin, and helping to unclog pores and reduce the appearance of acne. In hair care, it can also help with hair growth by unclogging hair follicles and stimulating blood flow to the scalp, and improve the health and appearance of the hair by removing build-up of product and environmental impurities. AHAs may be commercially available. Non-limiting examples of commercially available AHAs include high purity glycolic acid in GLYACID® from COAST SOUTHWEST™. In some instances, the glycolic acid, such as GLYACID®, does not contain formaldehyde. GLYACID® from COAST SOUTHWEST™ in some instances is available commercially as GLYACID® 70 HP and / or GLYACID® 99 HP. In some instances, the glycolic acid is produced using a saponification and purification process that does not use formaldehyde in the process. In some instances, the glycolic acid used has a purity of 55% or greater, such as 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%. In some instances, the glycolic acid used in the composition is supplied in an aqueous solution and / or as a powder.
[0068] Beta hydroxy acids (BHAs) are a group of naturally occurring acids that may be derived from willow bark, sweet birch, and other natural sources. BHAs contain a carboxylic acid and a hydroxyl group on the beta carbon. They are used in a variety of personal care products such as skin and hair care products. One of the most commonly used BHAs is salicylic acid. Salicylic acid is a BHA that is derived from willow bark and is a small molecule that can penetrate the skin easily. It works by exfoliating the skin, unclogging pores, and reducing theappearance of acne. Some benefits of salicylic acid include: improving the appearance of acne- prone skin, reducing the appearance of fine lines and wrinkles, enhancing skin texture and tone, improving the overall health and appearance of the skin, and helping to unclog pores and reduce the appearance of acne. In hair care, it can also help with hair growth by unclogging hair follicles and stimulating blood flow to the scalp, and improve the health and appearance of the hair by removing build-up of product and environmental impurities. BHAs may be commercially available.
[0069] The combination of ingredients can be used in different product forms to treat various skin conditions. By way of non-limiting examples, the combination of ingredients can be formulated in an emulsion (e.g., oil in water, water in oil), a gel, a serum, a gel emulsion, a gel serum, a lotion, a mask, a scrub, a wash, a cream, or a body butter.
[0070] The extracts described herein can be extracts made through extraction methods known in the art and combinations thereof. Non-limiting examples of extraction methods include the use of liquid-liquid extraction, solid phase extraction, aqueous extraction, ethyl acetate, alcohol, acetone, oil, supercritical carbon dioxide, heat, pressure, pressure drop extraction, ultrasonic extraction, etc. Extracts can be a liquid, solid, dried liquid, re-suspended solid, etc.B. Amounts of Ingredients
[0071] It is contemplated that the compositions of the present invention can include any amount of the ingredients discussed in this specification. The compositions can also include any number of combinations of additional ingredients described throughout this specification (e.g., pigments, or additional cosmetic or pharmaceutical ingredients). The concentrations of the any ingredient within the compositions can vary. In non-limiting embodiments, for example, the compositions can comprise, consisting essentially of, or consist of, in their final form, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%,0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%, 0.0550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%,3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%,5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%,6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%,7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%,9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or any range derivable therein, of at least one of the ingredients that are mentioned throughout the specification and claims. In non-limiting aspects, the percentage can be calculated by weight or volume of the total composition. A person of ordinary skill in the art would understand that the concentrations can vary depending on the addition, substitution, and / or subtraction of ingredients in a given composition.C. Vehicles
[0072] The compositions of the present invention can include or be incorporated into all types of vehicles and carriers. The vehicle or carrier can be a pharmaceutically or dermatologically acceptable vehicle or carrier approved for cosmetic applications. Nonlimiting examples of vehicles or carriers include water, glycerin, alcohol, oil, a silicon containing compound, a silicone compound, and wax. Variations and other appropriate vehicles will be apparent to the skilled artisan and are appropriate for use in the present invention. In certain aspects, the concentrations and combinations of the compounds,ingredients, and agents can be selected in such a way that the combinations are chemically compatible and do not form complexes which precipitate from the finished product.D. Structure
[0073] The compositions of the present invention can be structured or formulated into a variety of different forms. Non-limiting examples include emulsions (e.g., water-in-oil, water-in-oil-in-water, oil-in-water, silicone-in-water, water- in- silicone, oil-in-water-in-oil, oil- in-water-in-silicone emulsions), creams, lotions, solutions (both aqueous and hydro-alcoholic), anhydrous bases (such as lipsticks and powders), gels, masks, scrubs, body butters, peels, and ointments. Variations and other structures will be apparent to the skilled artisan and are appropriate for use in the present invention.E. Additional Ingredients
[0074] In addition to the combination of ingredients disclosed by the inventors, the compositions can also include additional ingredients such as cosmetic ingredients and pharmaceutical active ingredients. Non-limiting examples of these additional ingredients are described in the following subsections.1. Cosmetic Ingredients
[0075] The CTFA International Cosmetic Ingredient Dictionary and Handbook (2004 and 2008) describes a wide variety of non-limiting cosmetic ingredients that can be used in the context of the present invention. Examples of these ingredient classes include: fragrance agents (artificial and natural; e.g., gluconic acid, phenoxyethanol, and triethanolamine), dyes and color ingredients (e.g., Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10, and D&C yellow no. 11), flavoring agents / aroma agents (e.g., Stevia rebaudiana (sweetleaf) extract, and menthol), adsorbents, lubricants, solvents, moisturizers (including, e.g., emollients, humectants, film formers, occlusive agents, and agents that affect the natural moisturization mechanisms of the skin), water-repellants, UV absorbers (physical and chemical absorbers such as avobenzone, octocrylene, octinoxate, titanium dioxide, zinc oxide, etc.), essential oils, vitamins (e.g., A, B, C, D, E, and K), trace metals (e.g., zinc, calcium and selenium), anti-irritants (e.g., steroids and non-steroidal anti-inflammatories), botanical extracts (e.g., Aloe vera, chamomile, cucumber extract, Ginkgo biloba, ginseng, and rosemary), anti-microbial agents, antioxidants (e.g., BHT and tocopherol), chelating agents (e.g., disodiumEDTA and tetrasodium EDTA), preservatives (e.g., methylparaben and propylparaben), pH adjusters (e.g., sodium hydroxide and citric acid), absorbents (e.g., aluminum starch octenylsuccinate, kaolin, com starch, oat starch, cyclodextrin, talc, and zeolite), skin bleaching and lightening agents (e.g., hydroquinone and niacinamide lactate), humectants (e.g., sorbitol, urea, methyl gluceth-20, saccharide isomerate, and mannitol), exfoliants, waterproofing agents (e.g., magnesium / aluminum hydroxide stearate), skin conditioning agents (e.g., aloe extracts, allantoin, bisabolol, ceramides, dimethicone, hyaluronic acid, biosaccharide gum-1, ethylhexylglycerin, pentylene glycol, hydrogenated polydecene, octyldodecyl oleate, and dipotassium glycyrrhizate). Non-limiting examples of some of these ingredients are provided in the following subsections. a. UV Absorption and / or Reflecting Agents
[0076] UV absorption and / or reflecting agents that can be used in combination with the compositions of the present invention include chemical and physical sunblocks. Non-limiting examples of chemical sunblocks that can be used include benzophenones (oxybenzone, sulisobenzone, benzophenone, and benzophenone- 1 through 12), cinnamates (octyl methoxycinnamate (octinoxate), isoamyl p-methoxycinnamate, octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate, ethyl diisopropylcinnamate, glyceryl octanoate dimetho xycinnamate and ethyl methoxy cinnamate), cinnamate esters, salicylates (homomethyl salicylate, benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.), anthranilates, ethyl urocanate, homosalate, octisalate, dibenzoylmethane derivatives (e.g., avobenzone), octocrylene, octyl triazone, digalloyl trioleate, glyceryl aminobenzoate, lawsone with dihydroxyacetone, ethylhexyl triazone, dioctyl butamido triazone, benzylidene malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzoyl hexyl benzoate, bis diethylamino hydroxybenzoyl benzoate, bis benzoxazoylphenyl ethylhexylimino triazine, drometrizole trisiloxane, methylene bis-benzotriazolyl tetramethylbutylphenol, and bis-ethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidene camphor, and isopentyl 4-methoxy cinnamate. Non-limiting examples of physical sunblocks include, kaolin, talc, petrolatum and metal oxides (e.g., titanium dioxide and zinc oxide). b. Moisturizing Agents
[0077] Non-limiting examples of moisturizing agents that can be used with the compositions of the present invention include amino acids, chondroitin sulfate, diglycerin,erythritol, fructose, glucose, glycerin, glycerol polymers, glycol, 1,2,6-hexanetriol, honey, hyaluronic acid, hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol, maltitol, maltose, mannitol, natural moisturizing factor, PEG- 15 butanediol, poly glyceryl sorbitol, salts of pyrrolidone carboxylic acid, potassium PCA, propylene glycol, saccharide isomerate, sodium glucuronate, sodium PCA, sorbitol, sucrose, trehalose, urea, and xylitol.Other examples include acetylated lanolin, acetylated lanolin alcohol, alanine, algae extract, Aloe barbadensis, Aloe barbadensis extract, Aloe barbadensis gel, Althea officinalis extract, apricot (Primus armeniaca) kernel oil, arginine, arginine aspartate, Arnica montana extract, aspartic acid, avocado (Persea gratissima) oil, barrier sphingolipids, butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch (Betula alba) bark extract, borage (Borago officinalis) extract, butcherbroom (Ruscus aculeatus) extract, butylene glycol, Calendula officinalis extract, Calendula officinalis oil, candelilla (Euphorbia cerifera) wax, canola oil, caprylic / capric triglyceride, cardamom (Elettaria cardamomum) oil, carnauba (Copernicia cerifera) wax, carrot (Daucus carota sativa) oil, castor (Ricinus communis) oil, ceramides, ceresin, ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octanoate, ceteth-20, ceteth-24, cetyl acetate, cetyl octanoate, cetyl palmitate, chamomile (Anthemis nobilis) oil, cholesterol, cholesterol esters, cholesteryl hydroxystearate, citric acid, clary (Salvia sclarea) oil, cocoa (Theobroma cacao) butter, coco-caprylate / caprate, coconut (Cocos nucifera) oil, collagen, collagen amino acids, com (Zea mays) oil, fatty acids, decyl oleate, dimethicone copolyol, dimethiconol, dioctyl adipate, dioctyl succinate, dipentaerythrityl hexacaprylate / hexacaprate, DNA, erythritol, ethoxydiglycol, ethyl linoleate, Eucalyptus globulus oil, evening primrose (Oenothera biennis) oil, fatty acids, Geranium maculatum oil, glucosamine, glucose glutamate, glutamic acid, glycereth-26, glycerin, glycerol, glyceryl distearate, glyceryl hydroxystearate, glyceryl laurate, glyceryl linoleate, glyceryl myristate, glyceryl oleate, glyceryl stearate, glyceryl stearate SE, glycine, glycol stearate, glycol stearate SE, glycosaminoglycans, grape (Vitis vinifera) seed oil, hazel (Corylus americana) nut oil, hazel (Corylus avellana) nut oil, hexylene glycol, hyaluronic acid, hybrid safflower (Carthamus tinctorius) oil, hydrogenated castor oil, hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenated lanolin, hydrogenated lecithin, hydrogenated palm glyceride, hydrogenated palm kernel oil, hydrogenated soybean oil, hydrogenated tallow glyceride, hydrogenated vegetable oil, hydrolyzed collagen, hydrolyzed elastin, hydrolyzed glycosaminoglycans, hydrolyzed keratin, hydrolyzed soy protein, hydroxylated lanolin, hydroxyproline, isocetyl stearate, isocetyl stearoyl stearate, isodecyl oleate, isopropyl isostearate, isopropyl lanolate, isopropyl myristate,isopropyl palmitate, isopropyl stearate, isostearamide DEA, isostearic acid, isostearyl lactate, isostearyl neopentanoate, jasmine (Jasminum officinale oil, jojoba (Buxus chinensis) oil, kelp, kukui (Aleurites moluccana) nut oil, lactamide MEA, laneth-16, laneth-10 acetate, lanolin, lanolin acid, lanolin alcohol, lanolin oil, lanolin wax, lavender (Lavandula angustifolia) oil, lecithin, lemon (Citrus medica limonum) oil, linoleic acid, linolenic acid, Macadamia temifolia nut oil, maltitol, matricaria (Chamomilla recutita) oil, methyl glucose sesquistearate, methylsilanol PCA, mineral oil, mink oil, mortierella oil, myristyl lactate, myristyl myristate, myristyl propionate, neopentyl glycol dicaprylate / dicaprate, octyldodecanol, octyldodecyl myristate, octyldodecyl stearoyl stearate, octyl hydroxystearate, octyl palmitate, octyl salicylate, octyl stearate, oleic acid, olive (Olea europaea) oil, orange (Citrus aurantium dulcis) oil, palm (Elaeis guineensis) oil, palmitic acid, pantethine, panthenol, panthenyl ethyl ether, paraffin, PCA, peach (Prunus persica) kernel oil, peanut (Arachis hypogaea) oil, PEG-8 C12- 18 ester, PEG- 15 cocamine, PEG- 150 distearate, PEG-60 glyceryl isostearate, PEG-5 glyceryl stearate, PEG-30 glyceryl stearate, PEG-7 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-20 methyl glucose sesquistearate, PEG-40 sorbitan peroleate, PEG-5 soy sterol, PEG- 10 soy sterol, PEG-2 stearate, PEG-8 stearate, PEG- 20 stearate, PEG-32 stearate, PEG-40 stearate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate, pentadecalactone, peppermint (Mentha piperita) oil, petrolatum, phospholipids, plankton extract, polyamino sugar condensate, polyglyceryl-3 diisostearate, polyquatemium- 24, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, potassium myristate, potassium palmitate, propylene glycol, propylene glycol dicaprylate / dicaprate, propylene glycol dioctanoate, propylene glycol dipelargonate, propylene glycol laurate, propylene glycol stearate, propylene glycol stearate SE, PVP, pyridoxine dipalmitate, retinol, retinyl palmitate, rice (Oryza sativa) bran oil, RNA, rosemary (Rosmarinus officinalis) oil, rose oil, safflower (Carthamus tinctorius) oil, sage (Salvia officinalis) oil, sandalwood (Santalum album) oil, serine, serum protein, sesame (Sesamum indicum) oil, shea butter (Butyrospermum parkii), silk powder, sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, sodium palmitate, sodium PCA, sodium polyglutamate, soluble collagen, sorbitan laurate, sorbitan oleate, sorbitan palmitate, sorbitan sesquioleate, sorbitan stearate, sorbitol, soybean (Glycine soja) oil, sphingolipids, squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxy dimethicone, stearoxytrimethylsilane, stearyl alcohol, stearyl glycyrrhetinate, stearyl heptanoate, stearyl stearate, sunflower (Helianthus annuus) seed oil, sweet almond (Prunus amygdalus dulcis) oil, synthetic beeswax, tocopherol, tocopheryl acetate, tocopheryl linoleate,tribehenin, tridecyl neopentanoate, tridecyl stearate, triethanolamine, tristearin, urea, vegetable oil, water, waxes, wheat (Triticum vulgare) germ oil, and ylang ylang (Cananga odoratd) oil. c. Antioxidants
[0078] Non-limiting examples of antioxidants that can be used with the compositions of the present invention include acetyl cysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, cysteine, cysteine HC1, diamylhydroquinone, di-t- butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, esters of ascorbic acid, ethyl ferulate, ferulic acid, gallic acid esters, hydroquinone, isooctyl thioglycolate, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbate, natural botanical anti-oxidants such as green tea or grape seed extracts, nordihydroguaiaretic acid, octyl gallate, phenylthioglycolic acid, potassium ascorbyl tocopheryl phosphate, potassium sulfite, propyl gallate, quinones, rosmarinic acid, sodium ascorbate, sodium bisulfite, sodium erythorbate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolate, sorbityl furfural, thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50, tocopherol, tocophersolan, tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotinate, tocopheryl succinate, and tris (nony Ipheny l)pho sphite . d. Structuring Agents
[0079] In other non-limiting aspects, the compositions of the present invention can include a structuring agent. Structuring agent, in certain aspects, assist in providing rheological characteristics to the composition to contribute to the composition’s stability. In other aspects, structuring agents can also function as an emulsifier or surfactant. Non-limiting examples of structuring agents include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, stearic acid, palmitic acid, the polyethylene glycol ether of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, the polyethylene glycol ether of cetyl alcohol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.e. Emulsifiers
[0080] In certain aspects of the present invention, the compositions do not include an emulsifier. In other aspects, however, the compositions can include one or more emulsifiers. Emulsifiers can reduce the interfacial tension between phases and improve the formulation and stability of an emulsion. The emulsifiers can be nonionic, cationic, anionic, and zwitterionic emulsifiers (see U.S. Pat. Nos. 5,011,681; 4,421,769; 3,755,560). Non-limiting examples include esters of glycerin, esters of propylene glycol, fatty acid esters of polyethylene glycol, fatty acid esters of polypropylene glycol, esters of sorbitol, esters of sorbitan anhydrides, carboxylic acid copolymers, esters and ethers of glucose, ethoxylated ethers, ethoxylated alcohols, alkyl phosphates, polyoxyethylene fatty ether phosphates, fatty acid amides, acyl lactylates, soaps, TEA stearate, DEA oleth-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soya sterol, steareth-2, steareth-20, steareth-21, ceteareth-20, cetearyl glucoside, cetearyl alcohol, C12-13 pareth-3, PPG-2 methyl glucose ether distearate, PPG-5-ceteth-20, bis-PEG / PPG-20 / 20 dimethicone, ceteth-10, polysorbate 80, cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG- 100 stearate, arachidyl alcohol, arachidyl glucoside, and mixtures thereof. f. Silicone Containing Compounds
[0081] In non-limiting aspects, silicone containing compounds include any member of a family of polymeric products whose molecular backbone is made up of alternating silicon and oxygen atoms with side groups attached to the silicon atoms. By varying the -Si-O- chain lengths, side groups, and crosslinking, silicones can be synthesized into a wide variety of materials. They can vary in consistency from liquid to gel to solids.
[0082] The silicone containing compounds that can be used in the context of the present invention include those described in this specification or those known to a person of ordinary skill in the art. Non-limiting examples include silicone oils (e.g., volatile and non-volatile oils), gels, and solids. In certain aspects, the silicon containing compounds include silicone oils such as a polyorganosiloxane. Non-limiting examples of polyorganosiloxanes include dimethicone, cyclomethicone, polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, or mixtures of these and other organosiloxane materials in any given ratio in order to achieve the desired consistency and application characteristics depending upon the intended application (e.g., to a particular area such as the skin, hair, or eyes). A “volatilesilicone oil” includes a silicone oil have a low heat of vaporization, i.e. normally less than about 50 cal per gram of silicone oil. Non-limiting examples of volatile silicone oils include: cyclomethicones such as Dow Corning 344 Fluid, Dow Coming 345 Fluid, Dow Corning 244 Fluid, and Dow Coming 245 Fluid, Volatile Silicon 7207 (Union Carbide Corp., Danbury, Conn.); low viscosity dimethicones, i.e. dimethicones having a viscosity of about 50 cst or less (e.g., dimethicones such as Dow Corning 200-0.5 cst Fluid). The Dow Coming Fluids are available from Dow Corning Corporation, Midland, Michigan. Cyclomethicone and dimethicone are described in the Third Edition of the CTFA Cosmetic Ingredient Dictionary (incorporated by reference) as cyclic dimethyl polysiloxane compounds and a mixture of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units, respectively. Other non-limiting volatile silicone oils that can be used in the context of the present invention include those available from General Electric Co., Silicone Products Div., Waterford, N.Y. and SWS Silicones Div. of Stauffer Chemical Co., Adrian, Michigan. g. Exfoliating Agent
[0083] Exfoliating agents include ingredients that remove dead skin cells on the skin’s outer surface. These agents may act through mechanical, chemical, and / or other means. Nonlimiting examples of mechanical exfoliating agents include abrasives such as pumice, silica, cloth, paper, shells, beads, solid crystals, solid polymers, etc. Non-limiting examples of chemical exfoliating agents include acids and enzyme exfoliants. Acids that can be used as exfoliating agents include, but are not limited to, glycolic acid, lactic acid, citric acid, alpha hydroxy acids, beta hydroxy acids, etc. Other exfoliating agents known to those of skill in the art are also contemplated as being useful within the context of the present invention. h. Essential Oils
[0084] Essential oils include oils derived from herbs, flowers, trees, and other plants. Such oils are typically present as tiny droplets between the plant’s cells, and can be extracted by several method known to those of skill in the art (e.g., steam distilled, enfleurage (i.e., extraction by using fat), maceration, solvent extraction, or mechanical pressing). When these types of oils are exposed to air they tend to evaporate (i.e., a volatile oil). As a result, many essential oils are colorless, but with age they can oxidize and become darker. Essential oils are insoluble in water and are soluble in alcohol, ether, fixed oils (vegetal), and other organicsolvents. Typical physical characteristics found in essential oils include boiling points that vary from about 160° to 240° C and densities ranging from about 0.759 to about 1.096.
[0085] Essential oils typically are named by the plant from which the oil is found. For example, rose oil or peppermint oil are derived from rose or peppermint plants, respectively. Non-limiting examples of essential oils that can be used in the context of the present invention include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sage oil, Spanish rosemary oil, coriander oil, thyme oil, pimento berries oil, rose oil, anise oil, balsam oil, bergamot oil, rosewood oil, cedar oil, chamomile oil, sage oil, clary sage oil, clove oil, cypress oil, eucalyptus oil, fennel oil, sea fennel oil, frankincense oil, geranium oil, ginger oil, grapefruit oil, jasmine oil, juniper oil, lavender oil, lemon oil, lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrh oil, neroli oil, orange oil, patchouli oil, pepper oil, black pepper oil, petitgrain oil, pine oil, rose otto oil, rosemary oil, sandalwood oil, spearmint oil, spikenard oil, vetiver oil, wintergreen oil, or ylang-ylang. Other essential oils known to those of skill in the art are also contemplated as being useful within the context of the present invention. i. Thickening Agents
[0086] Thickening agents, including thickener or gelling agents, include substances which that can increase the viscosity of a composition. Thickeners include those that can increase the viscosity of a composition without substantially modifying the efficacy of the active ingredient within the composition. Thickeners can also increase the stability of the compositions of the present invention. In certain aspects of the present invention, thickeners include hydrogenated polyisobutene, trihydroxystearin, ammonium acryloyldimethyltaurate / VP copolymer, or a mixture of them.
[0087] Non-limiting examples of additional thickening agents that can be used in the context of the present invention include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides, and gums. Examples of carboxylic acid polymers include crosslinked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acids, and salts and esters of these acrylic acids and the substituted acrylic acids, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol (see U.S. Pat. Nos. 5,087,445; 4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary, Fourth edition, 1991, pp. 12 and 80). Examples of commercially available carboxylic acid polymers includecarbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerythritol (e.g., CARBOPOL™ 900 series from B. F. GOODRICH).
[0088] Non-limiting examples of crosslinked polyacrylate polymers include cationic and nonionic polymers. Examples are described in U.S. Pat. Nos. 5,100,660 ; 4,849,484; 4,835,206; 4,628,078; 4,599,379).
[0089] Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and laureth-7, multi-block copolymers of acrylamides and substituted acrylamides with acrylic acids and substituted acrylic acids.
[0090] Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Another example is an alkyl substituted cellulose where the hydroxy groups of the cellulose polymer is hydroxyalkylated (preferably hydroxy ethylated or hydroxypropylated) to form a hydroxyalkylated cellulose which is then further modified with a CIO -C30 straight chain or branched chain alkyl group through an ether linkage. Typically these polymers are ethers of C10-C30 straight or branched chain alcohols with hydroxyalkylcelluloses. Other useful polysaccharides include scleroglucans comprising a linear chain of (1-3) linked glucose units with a (1-6) linked glucose every three units.
[0091] Non-limiting examples of gums that can be used with the present invention include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. j. Preservatives
[0092] Non-limiting examples of preservatives that can be used in the context of the present invention include quaternary ammonium preservatives such as polyquatemium- 1 andbenzalkonium halides (e.g., benzalkonium chloride (“BAC”) and benzalkonium bromide), parabens (e.g., methylparabens and propylparabens), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.2. Pharmaceutical Ingredients
[0093] Pharmaceutical active agents are also contemplated as being useful with the compositions of the present invention. Non-limiting examples of pharmaceutical active agents include anti-acne agents, agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anti-cancer actives, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, biologically active proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatories, diaper rash treatment agents, enzymes, hair growth stimulants, hair growth retardants including DFMO and its salts and analogs, hemostatics, kerotolytics, canker sore treatment agents, cold sore treatment agents, dental and periodontal treatment agents, photosensitizing actives, skin protectant / barrier agents, steroids including hormones and corticosteroids, sunburn treatment agents, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatment agents, wound treatment agents, wound healing agents, etc.F. Kits
[0094] Kits are also contemplated as being used in certain aspects of the present invention. For instance, compositions of the present invention can be included in a kit. A kit can include a container. Containers can include a bottle, a metal tube, a laminate tube, a plastic tube, a dispenser, a pressurized container, a barrier container, a package, a compartment, a lipstick container, a compact container, cosmetic pans that can hold cosmetic compositions, or other types of containers such as injection or blow-molded plastic containers into which the dispersions or compositions or desired bottles, dispensers, or packages are retained. The kit and / or container can include indicia on its surface. The indicia, for example, can be a word, a phrase, an abbreviation, a picture, or a symbol.
[0095] The containers can dispense a pre-determined amount of the composition. In other embodiments, the container can be squeezed (e.g., metal, laminate, or plastic tube) to dispense a desired amount of the composition. The composition can be dispensed as a spray,an aerosol, a liquid, a fluid, or a semi-solid. The containers can have spray, pump, or squeeze mechanisms. A kit can also include instructions for employing the kit components as well the use of any other compositions included in the container. Instructions can include an explanation of how to apply, use, and maintain the compositions.EXAMPLES
[0096] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
[0097] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and / or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.Example 1 (Exemplary Formulations)
[0098] Formulations having the ingredients from Example 1 were prepared as topical skin or hair compositions. The formulation in Table 1 is an example of a topical skin and / or hair composition prepared as a serum.Table 1Example 2(Testing of a Formulation Having the Composition)
[0099] Table 2 represents the physical properties of a 70% aqueous solution of the glycolic acid used in an embodiment of the present invention. Table 3 represents testing of the formulation represented in Table 2. These formulations were tested to determine formaldehyde levels.Table 2Table 3*ND: Not Detected - test results show property not detected. 5ppm detection limit.Example 3 (Testing of a Formulation Having the Composition)
[0100] Tables 4 represents the physical properties of the glycolic acid in 99% crystalline form used in an embodiment of the present invention. Table 5 represents testing of the formulation represented in Table 4. These formulations were tested to determine formaldehyde levels.Table 4Table 5*ND: Not Detected - test results show property not detected. 5ppm detection limit.Example 4: Stability and Performance Testing
[0101] This example discloses stability testing and shelf-life data for some compositions disclosed herein. Batches of the test composition can be prepared and filled into vials with air-tight caps. Sealed vials can be stored at 2 - 8°C, 25°C / 60% Relative Humidity, 40°C / 75% relative humidity, or 50°C and uncontrolled humidity for a period of time. The test compositions can be sampled for characterization within 2 hours of filling into the vials, at 24 hours, at 1 week, at months 1, 2, 3, 6, 12, 18, 24, 36, 48, and 60. Characterization can include active ingredient(s) concentration by UPLC, color, structure, etc. The shelf-life can be the period of time in which there is 95% confidence that at least 50% of the tested characteristic (e.g., active ingredient(s) concentration, color, structure, etc.) is within a specification limit, such as less than a 10% change as compared to the results obtained with 2 hours of filling into the vials. It is expected that the product will have a shelf-life of over 12 months, 2, years, 3 years, 4 years, or 5 years.Example 5: Initial Testing of Formulation
[0102] Cytotoxicity and Dose Finding: The EpiDermFT-400 (EFT-400) model can be used for testing for cytotoxicity and dose-finding. This model consists of a three- dimensional human reconstructed epidermis that closely resembles actual human skin. To assess cytotoxicity, the formulation is applied to the EpiDermFT-400 model and incubated for a specific duration. Afterward, cell viability is evaluated using methods like MTT, MTS, or ATP assays, which measure metabolic activity or ATP content. By comparing viability data with untreated models, decrease in cell viability indicates cytotoxicity. In a dose-finding study, different concentrations of the formulation are applied to separate models, followed by incubation and viability assessment. The data obtained helps determine the concentration range that maintains cell viability while providing desired efficacy. The lowest concentration with minimal cytotoxic effects and optimal efficacy is typically selected. Additional tests, such as irritation testing and gene expression analysis, may be conducted alongside cytotoxicity assessments to comprehensively evaluate the safety and efficacy of skin care formulations.
[0103] Efficacy Testing: The SSP (Skin Sensitivity Profile) or ESP (Epidermal Stress Profile) gene expression panel can be used for efficacy testing with the utilization of the EFT- 400 model. First, a suitable panel of genes associated with skin sensitivity or epidermal stress is selected. These genes act as molecular markers and provide valuable insights into the formulation's effects on the skin at a genetic level. Next, the skincare formulation is applied to a designated area of the skin under controlled conditions. The EFT-400 model is utilized to analyze the expression levels of the selected genes. This model employs advanced techniques such as quantitative polymerase chain reaction (qPCR) or next-generation sequencing (NGS) to measure the gene expression profiles accurately. Once the formulation is applied, the skin is observed and monitored over a specific period to capture any changes or responses. Then analysis of the gene expression data obtained from the EFT-400 model is used to evaluate the formulation's ability to modulate gene expression patterns associated with skin sensitivity or epidermal stress.
[0104] Melanin Content Testing: The Melanoderm model (MelA or MelB) can be used to evaluate the effects of the formulations on melanin production in the skin. MelA and MelB consist of cultured cells or tissues that closely resemble the melanocytes present in human skin. These cells possess the ability to produce melanin, the pigment responsible for determining skin color. During the assay, the skincare formulation is applied to theMelanoderm model under controlled conditions. The formulation is carefully formulated to ensure its compatibility with the Melanoderm model and to simulate realistic skin application. After the application, the melanin content within the Melanoderm model is measured using various techniques such as spectrophotometry or image analysis. These methods enable the quantitative assessment of melanin levels, providing a measure of the formulation's impact on melanin production.
[0105] Cell-based Antioxidant Assay: The cell-based antioxidant assay can be used to assesses the antioxidant activity of a skin care composition. The assay works by measuring the ability of the composition to protect skin cells against oxidative stress, which is a major contributor to skin aging and damage. To perform the assay, skin cells are cultured in a multiwell plate and treated with the skin care composition at various concentrations. After a preincubation period, the cells are exposed to a source of oxidative stress, and DCFH-DA is added to the wells. The fluorescence intensity of DCF is then measured using a fluorescent plate reader, which is proportional to the amount of reactive oxygen species (ROS) generated in the cells. The antioxidant activity of the skin care composition can be calculated by comparing the fluorescence intensity of the treated cells to that of the positive control and negative control.
[0106] Cell-based Interleukin-1 Alpha (IL-la) Assay: The ELISA IL1 alpha on the keratinocyte cell line (Option A) assay can be used to assess the effects of a skin care formulation on the production of interleukin- 1 alpha (IL-la) in keratinocyte cells, which are crucial for skin health. First, keratinocyte cells are cultured in a multi-well plate and treated with different concentrations of the skin care formulation being tested, alongside appropriate control groups. The cells are then exposed to the formulation, allowing for interaction with its components. To stimulate an immune response, the cells are subjected to a specific triggering agent that induces IL-la production. This stimulation step ensures the activation of the cytokine production pathway. After an incubation period, the cell culture supernatant, containing the IL- la secreted by the keratinocyte cells, is collected. The supernatant is then analyzed using an enzyme-linked immunosorbent assay (ELISA) specific to IL-la. The ELISA employs specific antibodies that bind to IL-la, enabling its quantification. By measuring the intensity of the signal produced in the ELISA, the concentration of IL-la in the cell supernatant can be determined. This measurement can be conducted using a plate reader or similar instrument. The IL-la levels detected in the cell supernatant from the skin care formulation-treated cells are compared to the control groups. This comparative analysis can determine whether the formulation affects the production of IL-la in keratinocyte cells.
[0107] Cell-based Cytometric Beas Array (CBA) Assay: The CBA (Cytometric Bead Array) in keratinocyte cell line (Option B) assay can be used to evaluate the effects of a skin care formulation on the production of specific cytokines in keratinocyte cells. To conduct the assay, keratinocyte cells are cultured in a multi-well plate and treated with various concentrations of the skin care formulation under investigation, alongside appropriate control groups. The formulation is applied to the cells, allowing its components to interact with the cellular environment. Next, the cells are stimulated to induce cytokine production, typically by exposing them to specific agents or conditions known to trigger the release of cytokines. This stimulation step ensures the activation of cytokine production pathways. After an incubation period, the cell culture supernatant, containing the secreted cytokines produced by the keratinocyte cells, is collected. The supernatant is then subjected to Cytometric Bead Array (CBA) analysis, a flow cytometry-based technique. The analysis employs microbeads that are coated with specific antibodies capable of capturing and quantifying distinct cytokines. Using a flow cytometer, the fluorescence signals emitted by the bead-bound cytokines are measured. These signals are directly proportional to the concentration of the respective cytokines present in the sample. This allows for the detection and quantification of the cytokines released by the keratinocyte cells. The data obtained from the CBA analysis is then analyzed, comparing the cytokine levels in the cell supernatant from the skin care formulation-treated cells to those of the control groups to determine whether the formulation influences the production of specific cytokines in keratinocyte cells.
[0108] In Vitro Tyrosinase Activity Assay: The in vitro tyrosinase activity assay can be used to evaluate the effect of a skin care formulation on the activity of the enzyme tyrosinase. To conduct the assay, the tyrosinase enzyme is prepared and treated with the skin care formulation. The formulation-treated tyrosinase enzyme is then incubated under controlled conditions. Following the incubation period, a substrate such as L-DOPA (L-3,4- dihydroxyphenylalanine) is added to the reaction mixture. Tyrosinase converts the substrate into dopaquinone, leading to a measurable color change. The absorbance or intensity of the resulting color is measured using a spectrophotometer or similar instrument. The level of color intensity corresponds directly to the activity of tyrosinase. To assess the formulation's impact, the tyrosinase activity of the formulation-treated enzyme is compared to a control group, which may consist of untreated tyrosinase or a known tyrosinase activity inhibitor to determine the formulation's efficacy in addressing skin conditions related to pigmentation, such as hyperpigmentation or uneven skin tone.
[0109] Dermal Irritation Assay: The dermal irritation assay can be used to assess the potential dermal irritation caused by a skin care formulation. To conduct the assay, a small amount of the skin care formulation is applied to an isolated area of the skin, typically on the back of a laboratory animal or in vitro skin models. The formulation is left in contact with the skin for a specified period, following which the application site is examined for signs of irritation or inflammation. Several parameters can be evaluated during assessment, including the presence of erythema (redness), edema (swelling), and the formation of any other visible skin reactions. These observations are made at regular intervals following the application of the formulation. The severity of any observed skin reactions can be scored using a standardized system, such as the Draize scoring system.EXAMPLE 6 (Additional Assays)
[0110] Assays that can be used to determine the efficacy of any one of the ingredients or any combination of ingredients or compositions having said combination of ingredients disclosed throughout the specification and claims can be determined by methods known to those of ordinary skill in the art. The following are non-limiting assays that can be used in the context of the present invention. It should be recognized that other testing procedures can be used, including, for example, objective and subjective procedures.
[0111] B16 Pigmentation Assay: Melanogenesis is the process by which melanocytes produce melanin, a naturally produced pigment that imparts color to skin, hair, and eyes. Inhibiting melanogenesis is beneficial to prevent skin darkening and lighten dark spots associated with aging. This bioassay utilizes B16-F1 melanocytes, an immortalized mouse melanoma cell line, to analyze the effect of compounds on melanogenesis. The endpoint of this assay is a spectrophotometric measurement of melanin production and cellular viability. Bib- Fl melanocytes, can be cultivated in standard growth medium with 10% fetal bovine serum at 37°C in 10% CO2 and then treated with any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification for 6 days. Following incubation, melanin secretion is measured by absorbance at 405 nm and cellular viability is quantified.
[0112] Collagen Stimulation Assay: Collagen is an extracellular matrix protein critical for skin structure. Increased synthesis of collagen helps improve skin firmness and elasticity. This bioassay can be used to examine the effect of any one of the active ingredients,combination of ingredients, or compositions having said combinations disclosed in the specification on the production of procollagen peptide (a precursor to collagen) by human epidermal fibroblasts. The endpoint of this assay is a spectrophotometric measurement that reflects the presence of procollagen peptide and cellular viability. The assay employs the quantitative sandwich enzyme immunoassay technique whereby a monoclonal antibody specific for procollagen peptide has been pre-coated onto a microplate. Standards and samples can be pipetted into the wells and any procollagen peptide present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for procollagen peptide can be added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution can be added to the wells and color develops in proportion to the amount of procollagen peptide bound in the initial step using a microplate reader for detection at 450 nm. The color development can be stopped and the intensity of the color can be measured.
[0113] For generation of samples and controls, subconfluent normal human adult epidermal fibroblasts cultivated in standard growth medium with 10% fetal bovine serum at 37°C in 10% CO2, can be treated with each of the combination of ingredients or compositions having said combinations disclosed in the specification for 3 days. Following incubation, cell culture medium can be collected and the amount of procollagen peptide secretion quantified using a sandwich enzyme linked immuno-sorbant assay.
[0114] Elastin Stimulation Assay: Elastin is a connective tissue protein that helps skin resume shape after stretching or contracting. Elastin is also an important load-bearing protein used in places where mechanical energy is required to be stored. Elastin is made by linking many soluble tropoelastin protein molecules, in a reaction catalyzed by lysyl oxidase. Elastin secretion and elastin fibers can be monitored in cultured human fibroblasts by staining of cultured human fibroblasts using immunofluorescent antibodies directed against elastin.
[0115] Laminin and Fibronectin Stimulation Assay: Laminin and fibronectin are major proteins in the dermal-epidermal junction (DEJ) (also referred to as the basement membrane). The DEJ is located between the dermis and the epidermis interlocks forming fingerlike projections called rete ridges. The cells of the epidermis receive their nutrients from the blood vessels in the dermis. The rete ridges increase the surface area of the epidermis that is exposed to these blood vessels and the needed nutrients. The DEJ provides adhesion of the two tissue compartments and governs the structural integrity of the skin. Laminin andfibronectin are two structural glycoproteins located in the DEJ. Considered the glue that holds the cells together, laminin and fibronectin are secreted by dermal fibroblasts to help facilitate intra- and inter-cellular adhesion of the epidermal calls to the DEJ. Laminin and fibronectin secretion can be monitored by quantifying laminin and fibronectin in cell supernatants of cultured human fibroblasts treated for 3 days with culture medium with or without 1.0% final concentration of the test ingredient(s). Following incubation, laminin and fibronectin content can be measured using immunofluorescent antibodies directed against laminin and antibodies directed against fibronectin in an enzyme linked immuno- sorbant assay. Measurements are normalized for cellular metabolic activity, as determined by bioconversion of 3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
[0116] Tumor Necrosis Factor Alpha (TNF-a) Assay: The prototype ligand of the TNF superfamily, TNF-a, is a pleiotropic cytokine that plays a central role in inflammation. Increase in its expression is associated with an up regulation in pro -inflammatory activity. This bioassay can be used to analyze the effect of any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification on the production of TNF-a by human epidermal keratinocytes. The endpoint of this assay can be a spectrophotometric measurement that reflects the presence of TNF-a and cellular viability. The assay employs the quantitative sandwich enzyme immunoassay technique whereby a monoclonal antibody specific for TNF-a has been pre-coated onto a microplate. Standards and samples can be pipetted into the wells and any TNF-a present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for TNF-a can be added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution can be added to the wells and color develops in proportion to the amount of TNF-a bound in the initial step using a microplate reader for detection at 450 nm. The color development can be stopped and the intensity of the color can be measured. Subconfluent normal human adult keratinocytes cultivated in standard growth medium at 37°C in 5% CO2, can be treated with phorbol 12-myristate 13-acetate and any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification for 6 hours. PMA has been shown to cause a dramatic increase in TNF-a secretion which peaks at 6 hours after treatment. Following incubation, cell culture medium can be collected and the amount of TNF-a secretion quantified using a sandwich enzyme linked immuno-sorbant assay.
[0117] Antioxidant (AO) Assay: An in vitro bioassay that measures the total antioxidant capacity of any one of the ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification. The assay relies on the ability of antioxidants in the sample to inhibit oxidation. The antioxidant system of living organisms includes enzymes such as superoxide dismutase, catalase, and glutathione peroxidase; macromolecules such as albumin, ceruloplasmin, and ferritin; and an array of small molecules, including ascorbic acid, a-tocopherol, P-carotene, reduced glutathione, uric acid, and bilirubin. The sum of endogenous and food-derived antioxidants represents the total antioxidant activity of the extracellular fluid. Cooperation of all the different antioxidants provides greater protection against attack by reactive oxygen or nitrogen radicals, than any single compound alone. Thus, the overall antioxidant capacity may give more relevant biological information compared to that obtained by the measurement of individual components, as it considers the cumulative effect of all antioxidants present in plasma and body fluids. Anti-Oxidant capacity kits can be used as an in vitro bioassay to measure the total anti-oxidant capacity of each of any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification. The protocol can be followed according to manufacturer recommendations.
[0118] ORAC Assay: Oxygen Radical Absorption (or Absorbance) Capacity (ORAC) of any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification can also be assayed by measuring the antioxidant activity of such ingredients or compositions. Antioxidant activity indicates a capability to reduce oxidizing agents (oxidants). This assay quantifies the degree and length of time it takes to inhibit the action of an oxidizing agent, such as oxygen radicals, that are known to cause damage to cells (e.g., skin cells). The ORAC value of any one of the active ingredients, combination of ingredients, or compositions having said combinations disclosed in the specification can be determined by methods known to those of ordinary skill in the art (see U.S. Publication Nos. 2004 / 0109905 and 2005 / 0163880; and commercially available kits).
[0119] Mushroom tyrosinase activity assay: In mammalian cells, tyrosinase catalyzes two steps in the multi-step biosynthesis of melanin pigments from tyrosine (and from the polymerization of dopachrome). Tyrosinase is localized in melanocytes and produces melanin (aromatic quinone compounds) that imparts color to skin, hair, and eyes. Purified mushroom tyrosinase can be incubated with its substrate L-Dopa in the presence or absence of each of the active ingredients, any one of the combination of ingredients, or compositionshaving said combinations disclosed in the specification. Pigment formation can be evaluated by colorimetric plate reading at 490 nm. The percent inhibition of mushroom tyrosinase activity can be calculated compared to non-treated controls to determine the ability of test ingredients or combinations thereof to inhibit the activity of purified enzyme. Test extract inhibition was compared with that of kojic acid.
[0120] Matrix Metalloproteinase 3 and 9 Enzyme Activity (MMP3; MMP9) Assay: An in vitro matrix metalloprotease (MMP) inhibition assay. MMPs are extracellular proteases that play a role in many normal and disease states by virtue of their broad substrate specificity. MMP3 substrates include collagens, fibronectins, and laminin; while MMP9 substrates include collagen VII, fibronectins and laminin. This assay is designed to measure protease activity of MMPs using a thiopeptide as a chromogenic substrate (Ac-PLG-[2- mercapto-4-methyl-pentanoyl]-LG-OC2H5)5,6. The MMP cleavage site peptide bond is replaced by a thioester bond in the thiopeptide. Hydrolysis of this bond by an MMP produces a sulfhydryl group, which reacts with DTNB [5,5’-dithiobis(2- nitrobenzoic acid), Ellman’s reagent] to form 2-nitro-5- thiobenzoic acid, which can be detected by its absorbance at 412 nm (s=13,600 M-lcm-1 at pH 6.0 and above 7). The active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be assayed.
[0121] Matrix Metalloproteinase 1 Enzyme Activity (MMP1) Assay: An in vitro matrix metalloprotease (MMP) inhibition assay. MMPs are extracellular proteases that play a role in many normal and disease states by virtue of their broad substrate specificity. MMP1 substrates include collagen IV.
[0122] The assay is designed as an in vitro assay to measure MMP1 enzymatic activity. The active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be assayed. Test materials are incubated in the presence or absence of the purified enzyme and substrate to determine their protease inhibitor capacity.
[0123] Cyclooxygenase (COX) Assay: An in vitro cyclooxygenase- 1 and -2 (COX-1, -2) inhibition assay. COX is a bifunctional enzyme exhibiting both cyclooxygenase and peroxidase activities. The cyclooxygenase activity converts arachidonic acid to a hydroperoxy endoperoxide (Prostaglandin G2; PGG2) and the peroxidase component reduces the endoperoxide (Prostaglandin H2; PGH2) to the corresponding alcohol, the precursor ofprostaglandins, thromboxanes, and prostacyclins. This COX Inhibitor screening assay measures the peroxidase component of cyclooxygenases. The peroxidase activity is assayed colorimetrically by monitoring the appearance of oxidized N,N,N',N'-tetramethyl-p- phenylenediamine (TMPD). This inhibitor screening assay includes both COX-1 and COX-2 enzymes in order to screen isozyme- specific inhibitors. This assay can be used to analyze the effects of each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification on the activity of purified cyclooxygenase enzyme (COX-1 or COX-2).
[0124] Lipoxygenase (LO) Assay: An in vitro lipoxygenase (LO) inhibition assay. LOs are non-heme iron-containing dioxygenases that catalyze the addition of molecular oxygen to fatty acids. Linoleate and arachidonate are the main substrates for LOs in plants and animals. Arachadonic acid may then be converted to hydroxyeicosotrienenoic (HETE) acid derivatives, that are subsequently converted to leukotrienes, potent inflammatory mediators. This assay provides an accurate and convenient method for screening lipoxygenase inhibitors by measuring the hydroperoxides generated from the incubation of a lipoxygenase (5-, 12-, or 15- LO) with arachidonic acid. This assay can be used to determine the ability of each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification to inhibit enzyme activity. Purified 15- lipoxygenase and test ingredients can be mixed in assay buffer and incubated with shaking for 10 min at room temperature. Following incubation, arachidonic acid can be added to initiate the reaction and the mixtures can be incubated for an additional 10 min at room temperature. A substrate can be added to terminate catalysis and color progression can be evaluated by fluorescence plate reading at 490 nm. The percent inhibition of lipoxyganse activity can be calculated compared to non-treated controls to determine the ability of each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification to inhibit the activity of purified enzyme.
[0125] Elastase Assay: This assay can be used as an in vitro enzyme inhibition assay for measuring inhibition of elastase activity for each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification. This assay contains soluble bovine neck ligament elastin that can be labeled with dye such that the conjugate’s fluorescence can be quenched. The non-fluorescent substrate can be digested by elastase or other proteases to yield highly fluorescent fragments. The resulting increase in fluorescence can be monitored with a fluorescence microplate reader. Digestionproducts from the elastin substrate have absorption maxima at -505 nm and fluorescence emission maxima at -515 nm. The peptide, N-methoxysuccinyl-Ala-Ala-Pro-Val- chloromethyl ketone, can be used as a selective, collective inhibitor of elastase when utilizing this assay for screening for elastase inhibitors.
[0126] Production of Ceramides: Ceramides in cell or tissue samples can be labeled with a mouse monoclonal antibody anti-ceramide diluted to 1 / 50 for 2 hours at room temperature with an amplifier system biotin / streptavidin. Video microscope observation can be performed to view ceramides (pink stain).
[0127] Oil Control Assay: An assay to measure reduction of sebum secretion from sebaceous glands and / or reduction of sebum production from sebaceous glands can be assayed by using standard techniques known to those having ordinary skill in the art. In one instance, the forehead can be used. Each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be applied to one portion of the forehead once or twice daily for a set period of days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or more days), while another portion of the forehead is not treated with the composition. After the set period of days expires, then sebum secretion can be assayed by application of fine blotting paper to the treated and untreated forehead skin. This is done by first removing any sebum from the treated and untreated areas with moist and dry cloths. Blotting paper can then be applied to the treated and untreated areas of the forehead, and an elastic band can be placed around the forehead to gently press the blotting paper onto the skin. After 2 hours the blotting papers can be removed, allowed to dry and then transilluminated. Darker blotting paper correlates with more sebum secretion (or lighter blotting paper correlates with reduced sebum secretion.
[0128] Erythema Assay: An assay to measure the reduction of skin redness can be evaluated using a chroma meter. Skin erythema may be induced by applying a 0.2% solution of sodium dodecyl sulfate on the forearm of a subject. The area is protected by an occlusive patch for 24hrs. After 24 hrs, the patch is removed and the irritation-induced redness can be assessed using the a* values of the chroma meter. The a* value measures changes in skin color in the red region. Immediately after reading, the area is treated with the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification. Repeat measurements can be taken at regular intervals to determine the formula’s ability to reduce redness and irritation.
[0129] Skin Moisture / Hydration Assay: Skin moisture / hydration benefits can be measured by using impedance measurements. The impedance meter measures changes in skin moisture content. The outer layer of the skin has distinct electrical properties. When skin is dry it conducts electricity very poorly. As it becomes more hydrated increasing conductivity results. Consequently, changes in skin impedance (related to conductivity) can be used to assess changes in skin hydration. The unit can be calibrated according to instrument instructions for each testing day. A notation of temperature and relative humidity can also be made. Subjects can be evaluated as follows: prior to measurement they can equilibrate in a room with defined humidity (e.g., 30-50%) and temperature (e.g., 68-72°C). Three separate impedance readings can be taken on each side of the face, recorded, and averaged. The T5 setting can be used on the impedance meter which averages the impedance values of every five seconds application to the face. Changes can be reported with statistical variance and significance. Each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be assayed according to this process.
[0130] Skin Clarity and Reduction in Freckles and Age Spots Assay: Skin clarity and the reduction in freckles and age spots can be evaluated using chromometer. Changes in skin color can be assessed to determine irritation potential due to product treatment using the a* values of the chromameter. The a* value measures changes in skin color in the red region. This is used to determine whether each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification is inducing irritation. The measurements can be made on each side of the face and averaged, as left and right facial values. Skin clarity can also be measured using the chromameter. The measurement is a combination of the a*, b, and L values of the chromameter and is related to skin brightness, and correlates well with skin smoothness and hydration. Skin reading is taken as above. In one non-limiting aspect, skin clarity can be described as L / C where C is chroma and is defined as (a^+ b^ ) 1 / 2.
[0131] Skin Dryness, Surface Fine Lines, Skin Smoothness, and Skin Tone Assay: Skin dryness, surface fine lines, skin smoothness, and skin tone can be evaluated with clinical grading techniques. For example, clinical grading of skin dryness can be determined by a five point standard Kligman Scale: (0) skin is soft and moist; (1) skin appears normal with no visible dryness; (2) skin feels slightly dry to the touch with no visible flaking; (3) skin feels dry, tough, and has a whitish appearance with some scaling; and (4) skin feels very dry, rough, and has awhitish appearance with scaling. Evaluations can be made independently by two clinicians and averaged.
[0132] Clinical Grading of Skin Tone Assay: Clinical grading of skin tone can be performed via a ten point analog numerical scale: (10) even skin of uniform, pinkish brown color. No dark, erythremic, or scaly patches upon examination with a hand held magnifying lens. Microtexture of the skin very uniform upon touch; (7) even skin tone observed without magnification. No scaly areas, but slight discolorations either due to pigmentation or erythema. No discolorations more than 1 cm in diameter; (4) both skin discoloration and uneven texture easily noticeable. Slight scaliness. Skin rough to the touch in some areas; and (1) uneven skin coloration and texture. Numerous areas of scaliness and discoloration, either hypopigmented, erythremic or dark spots. Large areas of uneven color more than 1 cm in diameter. Evaluations were made independently by two clinicians and averaged.
[0133] Clinical Grading of Skin Smoothness Assay: Clinical grading of skin smoothness can be analyzed via a ten point analog numerical scale: (10) smooth, skin is moist and glistening, no resistance upon dragging finger across surface; (7) somewhat smooth, slight resistance; (4) rough, visibly altered, friction upon rubbing; and (1) rough, flaky, uneven surface. Evaluations were made independently by two clinicians and averaged.
[0134] Skin Smoothness and Wrinkle Reduction Assay With Methods Disclosed in Packman etal. (1978): Skin smoothness and wrinkle reduction can also be assessed visually by using the methods disclosed in Packman et al. (1978). For example, at each subject visit, the depth, shallowness and the total number of superficial facial lines (SFLs) of each subject can be carefully scored and recorded. A numerical score was obtained by multiplying a number factor times a depth / width / length factor. Scores are obtained for the eye area and mouth area (left and right sides) and added together as the total wrinkle score.
[0135] Skin Firmness Assay with a Hargens Ballistometer: Skin firmness can be measured using a Hergens ballistometer, a device that evaluates the elasticity and firmness of the skin by dropping a small body onto the skin and recording its first two rebound peaks. The ballistometry is a small lightweight probe with a relatively blunt tip (4 square mm-contact area) was used. The probe penetrates slightly into the skin and results in measurements that are dependent upon the properties of the outer layers of the skin, including the stratum corneum and outer epidermis and some of the dermal layers.
[0136] Skin Softness / Suppleness Assay with a Gas Bearing Electrodynamometer: Skin softness / suppleness can be evaluated using the Gas Bearing Electrodynamometer, an instrument that measures the stress / strain properties of the skin. The viscoelastic properties of skin correlate with skin moisturization. Measurements can be obtained on the predetermined site on the cheek area by attaching the probe to the skin surface with double-stick tape. A force of approximately 3.5 gm can be applied parallel to the skin surface and the skin displacement is accurately measured. Skin suppleness can then be calculated and is expressed as DSR (Dynamic Spring Rate in gm / mm).
[0137] Appearance of Lines and Wrinkles Assay with Replicas: The appearance of lines and wrinkles on the skin can be evaluated using replicas, which is the impression of the skin’s surface. Silicone rubber like material can be used. The replica can be analyzed by image analysis. Changes in the visibility of lines and wrinkles can be objectively quantified via the taking of silicon replicas form the subjects’ face and analyzing the replicas image using a computer image analysis system. Replicas can be taken from the eye area and the neck area, and photographed with a digital camera using a low angle incidence lighting. The digital images can be analyzed with an image processing program and are of the replicas covered by wrinkles or fine lines was determined.
[0138] Surface Contour of the Skin Assay with a Profilometer / Stylus Method: The surface contour of the skin can be measured by using the Profilometer / Stylus method. This includes either shining a light or dragging a stylus across the replica surface. The vertical displacement of the stylus can be fed into a computer via a distance transducer, and after scanning a fixed length of replica a cross-sectional analysis of skin profile can be generated as a two-dimensional curve. This scan can be repeated any number of times along a fix axis to generate a simulated 3-D picture of the skin. Ten random sections of the replicas using the stylus technique can be obtained and combined to generate average values. The values of interest include Ra which is the arithmetic mean of all roughness (height) values computed by integrating the profile height relative to the mean profile height. Rt which is the maximum vertical distance between the highest peak and lowest trough, and Rz which is the mean peak amplitude minus the mean peak height. Values are given as a calibrated value in mm. Equipment should be standardized prior to each use by scanning metal standards of know values. Ra Value can be computed by the following equation: Ra= Standardize roughness; Zm= the traverse (scan) length; and y = the absolute value of the location of the profile relative to the mean profile height (x-axis).
[0139] Efficacy Assay: In other non-limiting aspects, the efficacy of each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be evaluated by using a skin analog. Melanocytes, one of the cells in the skin analog, stain positively when exposed to L- dihydroxyphenyl alanine (L-DOPA), a precursor of melanin. The skin analog, can be treated with a variety of bases containing each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification or with the base alone as a control. Alternatively, an untreated sample of the skin analog can be used as a control.
[0140] Production of Filaggrin: Changes in the production of filaggrin in keratinocytes due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. Filaggrin is the precursor to Natural Moisturizing Factor (NMF) in the skin. Increased NMF increases the moisture content of the skin. Filaggrin production in treated and non-treated keratinocytes can be determined using a bioassay that analyzes filaggrin concentration in keratinocyte cell lysates. A non-limiting example of a bioassay that can be used to quantify filaggrin production is the western blotting protocol. For each sample, normal human epidermal keratinocytes (NHEK) are grown in EPI-200 growth media with calcium. NHEK are incubated in growth medium overnight at 37 °C in 5% CO2 prior to treatment. NHEK are then incubated in growth medium with 1% test compound / extract or no compound / extract (negative control) for 24 to 36 hours. The NHEK can then be washed, collected, and stored on ice or colder until lysed on ice using a lysis buffer and sonication. The protein concentrations of the samples can be determined and used to normalize the samples. The lysates can be stored at -80 °C until use in the quantification assay.
[0141] Production of Occludin: Changes in the production of occludin in keratinocytes due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. Occludin is a protein critical to the formulation of tight junctions and the skin’ s moisture barrier function. A non-limiting example of how occludin production in treated and non-treated keratinocytes can be determined is by the use of a bioassay that analyzes occludin concentration in keratinocyte cell lysates. The bioassay can be performed using western blotting protocol. For the samples, adult human epidermal keratinocytes (HEKa) can be grown at 37 °C and 5% CO2 for 24 hours in a growth media with calcium supplemented with a keratinocyte growthsupplement. The HEKa are then incubated in growth medium with test compound / extract, no compound / extract for negative control, or with ImM CaCh for positive control for 24 to 48 hours. The HEKa are then washed, collected, and stored on ice or colder until lysed on ice using a lysis buffer and sonication. The protein concentrations of the samples can be determined and used to normalize the samples. The lysates are stored at -80 °C until use in the bioassay.
[0142] This assay employs a quantitative western blotting immunoassay technique using an antibody specific for occludin to quantitatively detect occludin in the test samples. Cell samples are lysed and normalized for protein concentration. Normalized samples and molecular weight standards are then loaded and ran on a denatured protein separation gel using capillary electrophoresis. The proteins in the gel are then immobilized and immunoprobed using a primary antibody specific for occludin. The immobilized proteins are immunoprobed with an enzyme-linked detection antibody that binds the primary antibody. A chemiluminescent substrate solution is then added to the immobilized proteins to allow chemiluminescent development in proportion to the amount of occludin bound in the immobilization. The chemiluminescent development can be stopped at a specific time and the intensity of the chemiluminescent signal can be measured and compared to positive and negative controls.
[0143] Keratinocyte Monolayer Permeability: Changes in the permeability of a keratinocyte monolayer due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. Keratinocyte monolayer permeability is a measure of skin barrier integrity. Keratinocyte monolayer permeability in treated and non-treated keratinocytes can be determined using, as a non-limiting example, an in vitro vascular permeability. This assay analyzes endothelial cell adsorption, transport, and permeability. Briefly, adult human epidermal keratinocytes can be seeded onto a porous collagen-coated membrane within a collection well. The keratinocytes are then incubated for 24 hours at 37 °C and 5% CO2 in a growth media with calcium supplemented with a keratinocyte growth supplement. This incubation time allows the cells to form a monolayer and occlude the membrane pores. The media is then replaced with fresh media with (test sample) or without (non-treated control) test compounds / extracts and the keratinocytes are incubated for an additional 48 hours at 37 °C and 5% CO2. To determine permeability of the keratinocyte monolayer after incubation with / without the test compound / extract, the media is replaced with fresh media containing ahigh molecular weight Fluorescein isothiocyanate (FITC)-Dextran and the keratinocytes are incubated for 4 hours at 37 °C and 5% CO2. During the 4 hours incubation, FITC can pass through the keratinocytes monolayer and porous membrane into the collection well at a rate proportional to the monolayer’s permeability. After the 4 hour incubation, cell viability and the content of FITC in the collection wells can be determined. For the FITC content, the media in the collection well is collected and fluorescence of the media determined at 480 nm (Em) when excited at 520 nm. Percent permeability and percent change in comparison to the non-treated controls can be determined by the following equations: Percent Permeability = ((Mean Ex / Em of test sample) / Mean Ex / Em untreated control)* 100; Percent Change = Percent Permeability of test sample - Percent Permeability of untreated control.
[0144] Production of Hyaluronic Acid: Changes in the production of hyaluronic acid in human dermal fibroblasts due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. HA is a polysaccharide involved in stabilization of the structure of the matrix and is involved in providing turgor pressure to tissue and cells.
[0145] As one non-limiting example, HA production in treated and non-treated adult human dermal fibroblasts (HDFa) cells can be determined using a kit. In this assay, for production of samples, subconfluent HDFa cells are incubated at 37 °C and 10% CO2 in starvation medium (0.15% fetal bovine serum and 1% Penicillin Streptomycin solution in Dulbecco’s Modified Eagle Medium) for 72 hours prior to treatment. The cells are then incubated with fresh starvation medium with either test compound, positive control (phorbol 12-myristate 13-acetate and platelet derived growth factor) or no additive for 24 hours. Media is then collected and frozen at -80 °C until use in the assay.Briefly, the assay employs a quantitative sandwich enzyme immunoassay technique whereby a capture antibody specific for HA can be pre-coated onto a microplate. Standards and media from treated and untreated cells are pipetted into the microplate wells to enable any HA present to be bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked detection antibody specific for HA is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells to allow color development in proportion to the amount of HA bound in the initial step. The color development is stopped at a specific time and the intensity of the color at 450 nm can be measured using a microplate reader.
[0146] As another non-limiting example, human skin explants can be cultured in survival explants medium at 37° C in a humidified atmosphere supplemented with 5% CO2. Treatment of the explants can be carried out by topical application of sample product (n = 3) on days DO, D2, D3, D6, D8, and D9. The control explants (n = 3) receive no treatment except renewal of survival explants medium. Half of the volume of the survival medium can be renewed at days D3, D6, and D8. At D9, three explants of each condition can be taken and cut in half. A half explant is fixed in buffered formalin and the other is frozen at -80° C.
[0147] After 48 hours of fixation in ordinary Bouin and 24 hours in formalin, the samples can be dried and soaked in paraffin using an automatic tissue processor. Sections of 5 microns can be performed with a microtome and mounted on histological slides. Microscopic observations can be performed by optical microscopy, using a microscope. Images can be taken with a camera and CELLAD software. General morphology can be examined on paraffin sections stained with Masson's trichrome Goldner variant. The staining of hyaluronic acid can be performed with an anti-hyaluronic acid biotinylated protein (HABP) diluted to 1 / 100 for 1 hour at room temperature, with an amplifier system biotin / streptavidin.
[0148] Inhibition of Hyaluronidase Activity: Changes in the activity of hyaluronidase due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. Hyaluronidase is an enzyme that degrades HA. HA is a polysaccharide involved in stabilization of the structure of the matrix and is involved in providing turgor pressure to tissue and cells. As one non-limiting example, hyaluronidase activity can be determined using an in vitro protocol. Briefly, hyaluronidase type 1-S is added to microplate reaction wells containing test compound or controls. Tannic acid can be used as a positive control inhibitor, no test compound can be added for the control enzyme, and wells with test compound or positive control but without hyaluronidase can be used as a background negative control. The wells are incubated at 37 °C for 10 minutes before addition of substrate (HA). Substrate is added and the reactions incubated at 37 °C for 45 minutes. A portion of each reaction solution is then transferred to and gently mixed in a solution of sodium acetate and acetic acid pH 3.75 to stop that portion of the reaction (stopped wells). The stopped wells and the reaction wells should both contain the same volume of solution after addition of the portion of the reaction solution to the stopped wells. Both the reaction wells and the stopped wells are incubated for 10 minutes at room temperature. Absorbance at 600 nm is then measured for both the reaction wells and the stopped wells. Inhibition can be calculated using the following formulas: Inhibitor (or control) activity =(Inhibitor stopped wells absorbance at 600 nm - inhibitor reaction wells absorbance at 600 nm); Initial activity = control enzyme absorbance at 600 nm; Percent Inhibition = [(Initial activity / Inhibitor Activity)* 100]- 100.
[0149] Peroxisome Proliferator-Activated Receptor Gamma (PPAR-y) Activity: Changes in the activity of PPAR-y due to each of the active ingredients, any one of the combination of ingredients, or compositions having said combinations disclosed in the specification can be measured. PPAR-y is a receptor critical for the production of sebum. As one non-limiting example, the activity of PPAR-y can be determined using a bioassay that analyzes the ability of a test compound or composition to inhibit binding of a ligand. Briefly, fluorescent small-molecule pan-PPAR ligand, can be used to determine if test compounds or compositions are able to inhibit binding of the ligand to PPAR-y. The samples wells include PPAR-y and fluorescent ligand and either: test compound or composition (test); a reference inhibitor, rosiglitazone (positive control); or no test compound (negative control). The wells are incubated for a set period of time to allow the ligand opportunity to bind the PPAR-y. The fluorescence polarization of each sample well can then be measured and compared to the negative control well to determine the percentage of inhibition by the test compound or composition.
[0150] Cytokine array: Human epidermal keratinocytes are cultured to 70-80% confluency. The media in the plate is aspirated and 0.025% trypsin / EDTA is added. When the cells became rounded, the culture dish is gently tapped to release the cells. The trypsin / EDTA containing cells are removed from the culture dish and neutralized. Cells are centrifuged for 5 min. at 180 x g to form a pellet of cells. The supernatant is aspirated. The resulting pellet is resuspended in a media. The cells are seeded in 6- well plates at approximately 10-20% confluency. After the cells became approximately 80% confluent, the media is aspirated and 1.0 ml, along with phorbol 13-Myristate 12-acetate (“PMA”) (a known inducer of inflammation) and the test composition dilutions are added to two replicate wells (i.e., 1.0% ( lOOpl of 100X stock) and 0.1% (lOpl of 100X stock) test compositions are diluted into a final volume of 1 ml). The media is gently swirled to ensure adequate mixing. In addition, 1.0 ml of media is added to the control wells, with and without additional PMA. The plates are then incubated at 37±1°C and 5.0+1% CO2 for approximately 5 hours after dosing. Following this 5-hour incubation, all media is collected in conical tubes and frozen at -70°C.
[0151] For analysis, a 16-pad hybridization chamber is attached to 16-pad FAST slides arrayed in triplicate with 16 anti-cytokine antibodies plus experimental controls, and the slides are placed into a FASTFrame (4 slides per frame) for processing. Arrays are blocked for 15 min. at room temperature using 70 ml of blocking buffer. Blocking buffer is removed and 70 ml of each supernatant sample is added to each array. Arrays are incubated for 3 hours at room temperature with gentle agitation. Arrays are washed 3 times with TBS-T. Arrays are treated with 70 ml of an antibody cocktail, containing one biotinylated antibody corresponding to each of the arrayed capture antibodies. Arrays are incubated for 1 hour at room temperature with gentle agitation. Arrays are washed 3 times with TBS-T. Arrays are incubated with 70 ml of a solution containing streptavidin-Cy5 conjugate for 1 hour at room temperature with gentle agitation. Arrays are washed 3 times with TBS-T, quickly rinsed in de-ionized water, and dried.
[0152] Slides can be imaged in a confocal fluorescent imaging system. Array images can be saved and analyzed using IMAGING RESEARCH ARRAYVISION software. Briefly, spot intensities are determined by subtracting background signal. Spot replicates from each sample condition can be averaged and then compared to the appropriate controls.
[0153] Endothelial Tube Formation: Endothelial tube formation is involved in angiogenesis and micro-vessel capillary formation. Capillary formation and angiogenesis may contribute to redness and rosacea of the skin. The ability for endothelial cells to form tubes in the presence or absence of test extracts and compounds may be determined using a capillary tubule disruption assay with pre-formed primary human umbilical vein endothelial cells (HUVEC) in a cell culture system.
[0154] Briefly, HUVECs are cultured in vitro on Extracellular Matrix, which stimulates the attachment and tubular morphogenesis of endothelial cells to form capillary-like lumen structures. These in vitro formed capillary tubules are similar to human blood vessel capillaries in many aspects. The capillary tube assay is based on this phenomenon and is used for evaluation of potential vasculature targeting agents.
[0155] HUVEC cultures are grown in a 5% CO2 37°C cell incubator. The full growth medium for HUVECs is Endothelial Cell Basal Medium (EBM) supplemented with 2% fetal bovine serum (FBS), 12 pg / ml bovine brain extract, 1 pg / ml hydrocortisone, and 1 pg / ml GA- 1000 (gentamicin-amphothericin). HUVEC cultures between passage 3 and 8 may be used for all assay experiments.
[0156] HUVECs are pre-labeled with fluorescent agent Calcein AM and seeded in Extracellular Matrix coated 96-well culture plate with their full growth medium. After about four hours of the morphogenesis process, the endothelial capillary tubes should be formed. Then, test agent in designed doses in 50pl volume is applied into the formed capillary tubule cultures as treatment conditions. After about six hours of treatment, the endothelial tubule morphology in each well is examined by microscopy, imaged, and the capillary disrupting activities under treatment conditions can be quantitatively analyzed. Each test conditions can be conducted in duplicate wells, including controls.
[0157] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and / or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
Claims
CLAIMS1. A method of treating skin and / or hair in need thereof, the method comprising topically applying to the skin and / or hair an acidic composition comprising: a skin and / or hair active ingredient; and an alpha hydroxy acid and / or a beta hydroxy acid.
2. The method of claim 1, wherein the skin and / or hair active ingredient comprises a plant extract.
3. The method of claim 1, wherein the skin and / or hair active ingredient comprises an anthocyanin, delphinidin, and / or ellagic acid.
4. The method of claim 1, wherein the skin and / or hair active ingredient comprises maqui berry extract.
5. The method of claim 1, wherein the alpha hydroxy acid is glycolic acid, lactic acid, mandelic acid, and / or tartaric acid and / or wherein the beta hydroxy acid is salicylic acid and / or betaine salicylate.
6. The method of claim 1, wherein the composition is an emulsion, serum, gel, gel emulsion, gel serum, a cream, a cream-gel, a lotion, an oil, a cleanser, or a solution.
7. The method of claim 1, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the maqui berry extract is an aqueous, alcoholic, or hydroalcoholic extract.
8. The method of claim 1, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the composition comprises an effective amount of maqui berry extract to reduce oxidation of the skin and / or hair, decrease expression of tyrosinase, chelate copper, decrease skin redness, decrease melanin production, protect lipids of the F-layer of a hair fiber, maintain hydrophobicity of the skin and / or hair, maintain low porosity of hair, hydrate skin and / or hair, strengthen bonds of hair, and / or provide static charge to skin and / or hair when applied to skin and / or hair.
9. The method of claim 1, wherein the composition does not comprise formaldehyde.
10. The method of claim 1, wherein the composition comprises an alpha hydroxy acid comprising glycolic acid.
11. An acidic topical skin composition comprising: a skin and / or hair active ingredient; and an alpha hydroxy acid and / or a beta hydroxy acid.
12. The composition of claim 11, wherein the skin and / or hair active ingredient comprises a plant extract.
13. The composition of claim 11, wherein the skin and / or hair active ingredient comprises an anthocyanin, delphinidin, and / or ellagic acid.
14. The composition of claim 11, wherein the skin and / or hair active ingredient comprises maqui berry extract.
15. The composition of claim 11, wherein the alpha hydroxy acid is glycolic acid, lactic acid, mandelic acid, and / or tartaric acid and / or wherein the beta hydroxy acid is salicylic acid and / or betaine salicylate.
16. The composition of claim 11, wherein the composition is an emulsion, serum, gel, gel emulsion, gel serum, a cream, a cream-gel, a lotion, an oil, a cleanser, or a solution.
17. The composition of claim 11, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the maqui berry extract is an aqueous, alcoholic, or hydroalcoholic extract.
18. The composition of claim 11, wherein the skin and / or hair active ingredient comprises a maqui berry extract and the composition comprises an effective amount of maqui berry extract to reduce oxidation of the skin and / or hair, decrease expression of tyrosinase, chelate copper, decrease skin redness, decrease melanin production, protect lipids of the F-layer of a hair fiber, maintain hydrophobicity of the skin and / or hair, maintain low porosity of hair, hydrate skin and / or hair, strengthen bonds of hair, and / or provide static charge to skin and / or hair when applied to skin and / or hair.
19. The composition of claim 11, wherein the composition does not comprise formaldehyde.
20. The composition of claim 11, wherein the composition comprises an alpha hydroxy acid comprising glycolic acid.
